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ABSTRACT 
	
Due to the pressing need for new disease-modifying drugs for Alzheimer’s disease (AD), 
new treatment strategies and alternative drug targets are currently being heavily researched. One 
such strategy is to modulate protein kinases such as cyclin-dependent kinase 1 (CDK1), cyclin-
dependent kinase 5 (CDK5), glycogen synthase kinase-3 (GSK-3α and GSK-3β), and the protein 
kinase RNA-like endoplasmic reticulum kinase (PERK). AD intervention by reduction of 
amyloid beta (Aβ) levels is also possible through development of protein kinase C-epsilon (PKC-
ε) activators to recover α-secretase levels and decrease toxic Aβ levels, thereby restoring 
synaptogenesis and cognitive function. In this way, we aim to develop new AD drugs by 
targeting kinases that participate in AD pathophysiology.  
In our studies, comparative modeling was performed to construct 3D models for kinases 
whose crystal structures have not yet been identified. The information from structurally similar 
proteins was used to define the amino acid residues in the ATP binding site as well as other 
important sites and motifs. We searched for the common structural motifs and domains of GSK-
3β, CDK5 and PERK. Further, we identified the conserved water molecules in GSK-3β, CDK5 
and PERK through calculation of the degree of water conservation. We investigated the protein-
ligand interaction profiles of CDK1, CDK5, GSK-3α, GSK-3β and PERK based on molecular 
dynamics (MD) simulations, which provided a time-dependent demonstration of the interactions 
and contacts for each ligand. In addition, we explored the protein-protein interactions between 
CDK5 and p25. Small molecules which target this interaction may offer a prospective 
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therapeutic benefit for AD. In order to identify new modulators for protein kinase targets in AD, 
we implemented three virtual screening protocols. The first protocol was a combined ligand- and 
protein structure-based approach to find new PERK inhibitors. In the second protocol, protein 
structure-based virtual screening was applied to find multiple-kinase inhibitors through parallel 
docking simulations into validated models of CDK1, CDK5 and GSK-3 kinases. In the third 
protocol, we searched for potential activators of PKC-ε based on the structure of its C1B domain. 
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CHAPTER 1. INTRODUCTION 
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1.1. Alzheimer’s disease 
Alzheimer’s disease (AD) is a disease of the brain, which is characterized by 
deterioration in perception, physical function, and behavior1. About 25 million people in the 
world are reported to have dementia2, 3 (weakening of intellectual abilities that rigorously limits 
activities of daily life), with the most common type of dementia being AD4. Approximately 6.8 
million individuals in the United States are living with dementia, and about 5.3 million have 
been diagnosed with AD5 (Figure 1.1). It is the sixth leading cause of all deaths and the ﬁfth 
leading cause of death in people aged ≥ 65 years in USA6. As the elderly population remains to 
increase, these figures are expected to nearly double by 2020, and quadruple by 2040. AD is 
predicted to affect 1 in 85 people worldwide by 20507. 
 
Figure 1.1. Number of people age 65 and older in the U.S divided by age group8. Population 
with AD, 2010 to 2050. Reprinted from: Alzheimer's & Dementia, 11(3), Alzheimer’s 
Association, 2015, Alzheimer's disease facts and figures, 332-384, Copyright (2015), with 
permission from Elsevier. 
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AD has arisen as a serious public health concern, placing a huge burden on the 
individual, family, community, and health care resources9. The cost of caring for the growing 
number of people with dementia remains to grow and the World Health Organization (WHO) 
estimated that, in the population over 60 years old, dementia contributes to 11.2% of years spent 
living with a disability—more than stroke, cardiovascular disease, or cancer.  Based on the 
current expenses of $226 billion in 2015, AD is considered the most expensive disease in the 
USA10. In 2015, one of each five Medicare dollars was spent on AD, and by 2050 AD is 
expected to cost $1.1 trillion per year11, 12. Therefore, AD will cause a 500% increase in annual 
Medicare and Medicaid spending by 205013. 
 
1.1.1. Pathogenesis 
Out of all the theories developed to elucidate the pathogenesis of AD, the most broadly 
accepted are the amyloid beta (Aβ) and the tau hyperphosphorylation hypothesis14, 15. This 
caused the therapies under exploration to target exclusively Aβ production/aggregation and 
tauopathies. According to the Aβ hypothesis, an unusual overproduction of Aβ (a 42-amino acid 
peptide) is responsible for the neurotoxicity, which leads to senile (neuritic) plaque formation 
and neuronal death16-18. Aβ is derived from the transmembrane (TM) precursor, amyloid 
precursor protein (APP), by the action of β-secretase and γ-secretase19. The β-secretase enzyme, 
or BACE-1 (βeta-site APP-cleaving enzyme 1), catalyzes the first cleavage that produces soluble 
APP-β and a C-terminal membrane-bound region, C99, which is the immediate substrate for the 
γ-secretase enzyme20-22 (Figure 1.2). There has been intense research on Aβ peptide, and the 
polymerization of Aβ into neurotoxic aggregates is considered a key event in the pathological 
cascade that results in AD.  
 
 
4 
 
 
Figure 1.2. The breakup of APP by secretase enzymes23. Under normal conditions, APP is 
favorably cleaved by α-secretase. In AD, β-secretase and then γ-secretase cleave APP to generate 
the neurotoxic Aβ peptides. The plaques are then formed by the aggregation of the Aβ peptides 
into oligomeric aggregates. Reprinted by permission from Macmillan Publishers Ltd: [Nature 
Reviews] (Götz J and Ittner LM, (7): 532-44, Copyright (2008). 
 
Consistent with the tau hyperphosphorylation hypothesis, tau protein, a microtubule-
connected protein that strengthens the neuronal cytoskeleton, is aberrantly hyperphosphorylated 
and groups into neurofibrillary tangles (NFT), leading to neuronal death24-26 (Figure 1.3). The 
balance between the activities of tau kinases and phosphatases controls the extent of tau 
phosphorylation, so disturbance of this balance causes atypical tau phosphorylation, resulting in 
reducing the affinity of tau for microtubules. Tau aggregation is strongly linked to the severity of 
AD more than Aβ plaques. However, it has also been suggested that the changes in the tau 
protein and the resulting NFT tangle formation are stimulated by toxic concentrations of Aβ27. 
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Figure 1.3. Tau is a soluble protein23, but hyperphosphorylation causes the tau monomers to 
bind together budding insoluble aggregates, which then affects normal neuronal function. 
Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews] (Götz J and Ittner 
LM, (7): 532-44), Copyright (2008). 
 
1.1.2. Risk factors 
There is now strong evidence of probable risk and protective factors for AD, dementia 
and cognitive decline28, 29. AD has a number of contributing elements that lead to its composite 
etiology, but age is the most important risk factor. Other factors that may lead to AD are brain 
trauma, stroke, obesity, diabetes, hypertension, dyslipidemia, hyperhomocysteinemia, and metal 
exposure30-32. Several genetic mutations are known to be associated with AD, such as mutations 
in APP or presenilin1, 33-35. Presenilin is a component of the γ-secretase enzyme complex that 
degrades APP into Aβ, leading to familial AD. Another genetic origin may be the isoforms of 
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ApoE4 (the cholesterol transporter apolipoprotein) which, when homozygotic, raise the risk of 
developing AD by about 15 times36. 
 
1.1.3. Diagnosis 
Scientists continue to look for diagnostic tools with suitable precision and accuracy to be 
used while the patient is in the presymptomatic phase37, 38. Currently, conclusive diagnosis of AD 
can only be made postpartum because of the inadequate understanding of its etiology39. 
Therefore, there is an urgent need for an early biomarker of AD that could be used for 
identifying presymptomatic patients for clinical trials, and, to allow treatment to be started at an 
early phase of the disease40, 41.   
Analysis of cerebrospinal fluid (CSF) levels of tau, phosphorylated tau or the ratio 
between them, has been found to show neuronal degeneration associated with NFT 
accumulation42-44. However, the strongest biomarkers for AD are brain imaging studies using 
magnetic resonance imaging (MRI) or positron emission tomography (PET)45, 46. MRI can be 
used to identify the characteristic pattern of degeneration in the temporal lobes. The 
accumulation of Aβ can be detected through the use of radioactive tracers such as [18F]-
florbetapir47, 48 and Pittsburgh compound B (PiB)49-51 (Figure	 1.4). Fluorodeoxyglucose- (FDG-) 
PET imaging52, 53 can also be used to detect hypometabolism in the temporoparietal region, 
which has been shown to distinguish successfully between AD and normal controls. In addition, 
a complete medical history, mental status exam and blood tests are required to exclude other 
origins of dementia-like symptoms. 
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[18F]-florbetapir                                                                           [18F]-fluorodeoxyglucose 
 
PiB compound 
Figure 1.4. Structures of [18F]-florbetapir, [18F]-fluorodeoxyglucose and the PiB compound. 
 
1.1.4. Current therapies 
Since much of AD pathophysiology at the molecular level has yet to be understood fully, 
there is no recognized cure for AD1. Only two classes of therapeutics (Figure 1.5) are presently 
available for AD management54: the acetylcholinesterase (AChE) inhibitors (rivastigmine, 
galantamine and donepezil) and one N-methyl D-aspartate (NMDA) receptor antagonist 
(memantine)55-57. Unfortunately, these drugs only target the behavioral features of AD without 
much enhancement of mental abilities or long-term quality of life. The cholinesterase inhibitors 
are indicated for the treatment of patients in the mild to moderate stages of AD58. Memantine 
works by increasing the concentration of glutamate, a neurotransmitter involved in learning and 
memory, and is used for the treatment of moderate to severe AD59. There is also evidence that 
memantine provides additional benefits in patients concurrently taking donepezil60, 61. Despite 
the benefits these AD drugs offer, their use is limited, since they are effective for only 
approximately one year and in only about half of the individuals to whom they are prescribed62. 
OHO
OH OH18F
H
OH
N
S
NH
11CH3
PiB compound
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     Figure 1.5. Structures of memantine, galantamine, rivastigmine and donepezil. 
 
1.1.5. Agents under investigation 
AD has been considered as a research priority because, although there are few existing 
approved treatments, there is a need to develop more effective disease-modifying drugs. 
Therefore, there is an ongoing enormous research effort targeting the development of effective 
drugs. Many of the proposed disease-modifying AD treatments target the production and 
clearance of Aβ in order to slow the disease progress and to improve behavioral and mental 
symptoms63.  
Table 1.1 shows some of the amyloid related therapeutics currently or previously tested 
as treatment for AD. Amyloid related therapies64 presently under investigation include β-
secretase inhibitors65, γ-secretase modulators66, α-secretase modulators67, Aβ aggregation 
inhibitors68, metal chelators69 and immunotherapy70. β-secretase inhibitors aim to decrease the 
concentration of Aβ1–42 peptides71. These agents target an important step of Aβ production (the 
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cleavage of APP) and, therefore, have some promising prospects. However, the active site of 
secretases may be difficult to target because the molecules that bind to their active site tend not 
to have properties that offer easy access through the blood-brain barrier (BBB)72. One such small 
molecule drug, tarenflurbil73 (Table 1.1), which demonstrated good activity in Phase 2 clinical 
trials, did not show considerable-enough benefits in the following larger controlled trials, a result 
which was attributed to the challenge of BBB crossing.   
Inhibiting the aggregation of Aβ is another mechanism of possible therapies being 
investigated. One example of an aggregation inhibitor, tramiprosate74 (Table 1.1), did not 
sufficiently inhibit Aβ aggregation, according to the results of clinical trials. Because Aβ may be 
susceptible to unusual interaction with metal ions in the synaptic region, ionophores were 
suggested as potential therapies for AD. Studies have shown the combined involvement of 
copper and zinc in the precipitation of Aβ and plaques formation. Phase 2 studies of the metal 
chelator, clioquinol75 (Table	 1.1) have shown clinical benefit and reduced CSF Aβ 
concentrations, but did not show significant benefits in Phase 3 trials76. There are a number of 
factors that influence the processing, aggregation, and clearance of Aβ, posing potential 
challenges. Therefore, many drugs continue to fail in clinical trials. 
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Table 1.1. Amyloid related therapeutics, which are currently being tested or previously were 
tested as treatments for AD. 
      Structure/Name FDA status Target 
 
Phase 2 Increases the expression of 
α-secretase77 
 
Failed in Phase 2  γ-secretase inhibitor78 
 
Phase 3 BACE inhibitor79 
 
Phase 3 Inhibitor of RAGE, the 
receptor for advanced 
glycation end-products80 
 
 
Phase 2 γ-secretase modulator81 
O
OH
O
Acitretin
S
O
O N
NO
N F
F
F F
O NH2Cl
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N
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Failed in Phase 2 Metal protein-attenuating 
compound82 
 
Failed in Phase 2 Prevents Aβ oligomers from 
aggregating83 
 
Failed in Phase 3 γ-secretase modulator73 
 
Failed in Phase 2 γ-secretase modulator84 
 
Failed in Phase 2 Synaptic vesicle protein 
modulator85 
 
 
Failed in Phase 2 BACE inhibitor79 
 
Phase 2 Metal protein-attenuating 
compound86 
Cl
I
OH
N
Clioquinol
OH
OH
HO
HO
OH
OH
ELND005
F
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HO
Tarenflurbil
O
OH
Ibuprofen
O
NH2
NO
Levetiracetam
S
N
O
N
H
O
N
F
FH2N
LY2886721
N N
OH
Cl
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Failed in Phase 3 γ-secretase inhibitor87 
 
Phase 3 BACE inhibitor88 
 
Phase 2 Inhibits the expression of 
BACE189 
 
 
 
Failed in Phase 2 Aggregation inhibitor84 
 
A few of the new therapies have targeted tau phosphorylation or tau aggregation. Table 
1.2 shows the tau-related therapeutics which are currently or previously tested as treatments for 
AD. These include GSK-3β inhibitors and tau aggregation inhibitors (Table 1.2). Lithium’s 
benefits of reducing tau pathology have been established in animal models of AD.  Tideglusib90 
is a thiadiazolinedione derivative and a non-ATP competitive GSK-3 inhibitor, and it became a 
candidate in Phase IIb trials. The extended Phase II trial (60-day treatment) did not reveal 
adverse effects but produced no significant clinical benefits. Another approach to reduce tau 
pathology has been to directly inhibit tau aggregation; preliminary evidence suggests that 
methylene blue (INN: methylthioninium chloride)91 (Table 1.2) may be particularly beneficial. 
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Table 1.2. Tau related therapeutics which are currently or previously tested as treatment for AD.  
      Structure/Name FDA status  Target 
Lithium Phase 3 GSK-3β inhibitor92 
 
Failed in Phase 2 Tau aggregation 
inhibitor93 
 
Failed in Phase 2 Microtubule stabilizer94 
 
Failed in Phase 2 GSK-3β inhibitor95 
 
                  Docetaxel 
           Phase 1 Microtubule stabilizer96 
 
            Phase 3 Stabilized form of 
methylthioninium 
chloride, to improve the 
drug's absorption, 
bioavailability, and 
tolerability97 
N S+ N
N
Cl-
Methylthioninium chloride
O
O
O
O
OH
HO S
N
Epothilone D
N
ON
S
O
Tideglusib
OO
O
O
OHO
O
HN
OO OH
O
O
OO
O
N
N
N+S
Cl-
TRx0237
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1.2. Protein kinases 
Protein kinase-mediated cell signaling pathways play important roles in cell growth, 
metabolism, differentiation, and apoptosis by catalyzing phosphorylation of about one third of 
the proteome98. This is accomplished by transfer of the terminal γ-phosphate group of adenosine 
triphosphate (ATP) to the hydroxyl acceptor group present on the side chains of the substrate 
serine, threonine, or tyrosine (sometimes also histidine) residues99 (Scheme 1.1). Therefore, the 
nucleophilic attack is performed by the hydroxyl oxygen of the substrate molecule.  
 
 Scheme 1.1. Phosphoryl transfer reaction.  One third of the proteome is phosphorylated by 
different protein kinases.  
 
Regulation of kinases has been implicated in a number of disease situations, including 
cancer, diabetes and AD; this makes kinases a greatly targeted group of drug targets. To date, 
numerous protein kinase experimental three-dimensional structures have been identified in both 
active and inactive states, aiding general understanding of protein kinase mechanism100.  
Protein kinases have a general well-preserved folding arrangement101, which involves two lobes: 
a smaller N-terminal lobe (N-lobe) contains mostly β-sheets and a larger C-terminal lobe (C-
lobe) contains mostly α-helices. The two lobes form a hydrophobic cleft, which houses the ATP 
molecule (Figure 1.6).  
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A)            B) 
 
Figure 1.6. A) The overall structural fold of the protein kinases. The N-lobe (shown in blue) is 
mainly made of β-sheets, connecting loops and one functionally essential helix. The C-lobe 
(shown in red) is mainly made of α-helices and connecting loops. B) The N-lobe forms a 
hydrophobic pocket (hinge region), which accommodates the adenine ring of ATP. 
 
The glycine-rich loop102, located in the N-lobe, acts as a lid on top of the ATP, assisting 
the transfer of the γ-phosphate to the substrate (Figure 1.7). The activation segment103 (DFG 
loop) contains the phosphorylation site that, upon phosphorylation, induces a conformational 
movement on the loop that allows the substrate binding and converts the kinase from an inactive 
form to a catalytically active form (Figure 1.7). 
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Figure 1.7. Protein kinase structural features: hinge region (yellow loop), C-helix (pink), 
glycine-rich loop (yellow beta-sheet) and activation loop (green loop). 
 
The aspartate residue from the generally conserved Asp–Phe–Gly (DFG) motif forms 
polar contacts with all three of the ATP phosphates, directly or through coordinating magnesium 
atoms104, 105. The Mg2+ ions neutralize the triphosphates allowing the positioning of the ATP 
molecule in the hydrophobic active site106 (Figure 1.8). The important lysine residue, which is 
conserved in every known kinase, binds the α- and β-phosphates of the ATP molecule and forms 
an important polar contact with a conserved glutamic acid residue107 (Figure 1.9). There are two 
major possibilities to inhibit protein kinases: ATP competitive inhibition and non-ATP 
competitive inhibition108. The non-ATP competitive inhibitors, for example, substrate 
competitive inhibitors, usually participate in a weak binding interaction with the enzyme109. Non-
ATP competitive inhibitors do not compete with the intracellular ATP, which presents in high 
concentration, and therefore have a pharmacological benefit. 
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Figure 1.8. The Mg ions neutralize the triphosphates permitting the placing of the ATP molecule 
in the hydrophobic pocket. 
 
 
  Figure 1.9. The ionic interaction between the conserved Lys72 and Glu91 residue. 
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1.3. Protein kinases as AD targets 
 
It has become clear that AD is a cross-linked disease with numerous pathological events. 
A faulty mechanism demonstrated in AD is protein phosphorylation regulated by protein kinases. 
Studies have shown that several kinases initiate the excess formation of plaques and of 
neurofibrillary tangles leading to Alzheimer’s-like dementias110 (Figure 1.10). Protein kinases 
are emerging therapeutic targets for AD, particularly after the failure of several agents that target 
the Aβ cascade to demonstrate therapeutic usefulness in clinical testing. One therapeutic goal is 
to inhibit the protein kinases that mediate the phosphorylation of amino acid residues mostly 
found to be phosphorylated in Alzheimer’s brain111. However, protein kinases’ involvement in 
many vital signaling pathways has the possibility to cause many off-target effects112. Thus, 
protein kinase inhibitors appropriate for AD treatment have to strike a balance between the 
different pathways by moderate inhibition and favorable pharmacokinetics. 
Out of the seven known kinase families, some members of five families (CMGC, CaMK, 
AGC, STE, and TKL) have been studied in the context of AD113. Several kinases are involved in 
the four primary domains relevant to the neurodegeneration found in AD including APP 
processing, tau hyperphosphorylation, neuroinflammation, and neurotoxicity114. These kinases 
include cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 5 (CDK5), glycogen 
synthase kinase-3 (GSK-3α and GSK-3β), protein kinase C-epsilon (PKC-ε) and the protein 
kinase RNA-like endoplasmic reticulum kinase (PERK)115. In the following sections we will 
describe the role of each kinase in the pathogenesis of AD.  
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Figure 1.10. Protein kinases have several actions in the pathology of AD116. They are involved 
in the mRNA splicing of tau protein, phosphorylation of tau protein at multiple sites, and APP 
cleavage by the β- and γ-secretases to form Aβ. Reprinted from: J Exp Clin Med, 4(3), Liu HC, 
Leu SJ, Chuang DM. Roles of Glycogen Synthase Kinase-3 in Alzheimer’s Disease: From 
Pathology to Treatment Target, 135-139, Copyright (2012), with permission from Elsevier. 
 
1.3.1. CDK1 as a kinase target for AD 
CDK1 acts in the cell cycle by modulating the centrosome cycle and mitotic onset. CDK1 
interacts with multiple cyclins to support G1 phase progress and its transition to S phase117. It 
phosphorylates several cellular proteins including APC, AMPH and Bcl-xL98. CDK1 is regulated 
by phosphorylation at Thr 14 or Tyr 15 to inactivate the enzyme, and phosphorylation at Thr 161 
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to activate it118. Also CDK1 binding to cyclin-B is an essential step to relocate the kinase 
complexes into the nucleus119. The capability of a CDK1 inhibitor to stop Aβ cytotoxicity 
suggests that CDK1 is a prospective target of AD120. Studies have established the important role 
of the CDK1 enzyme in Aβ cytotoxicity through its phosphorylation of Aβ121. The location of 
the gene that expresses CDK1 within the same locus on chromosome 10 that is associated with 
increased Aβ levels is evidence of this role122. The CDK1 gene also contains a single nucleotide 
polymorphism, which affects the amino acid residue 59; an isoform contains an arginine residue 
and another contains a glycine residue at position 59123. The affected N-terminal region of CDK1 
contains the cyclin binding site and the amino acid changes could therefore impact the kinase 
activity. The levels of both CDK1 protein and cyclin B1 are elevated in AD brains124. The Aβ 
peptide binds to cyclin B1 and increases the activity of the CDK1/cyclin B1 complex125. Since 
there is a clear connection between the amyloid and tau theories in etiology of AD, the ability of 
Aβ to directly increase the activity of CDK1 may also contribute to the phosphorylation 
abnormality features of AD126, 127. Aβ toxicity involves other members of the CDK family, as 
cyclin B1 is able to activate kinases other than CDK1128. The ability of CDK1 inhibitors to 
prevent Aβ cytotoxicity suggests that CDK1 is a potential target of AD therapeutic agents 
(Figures 1.11 and 1.12). Several chemical classes inhibit CDK1 including oxoindoles, 
pyrazolo[3,4-b]pyridines, indazole analogs, indolin-2-ones, pyridine derivatives, purine 
derivatives, pyrimidine derivatives and flavopiridol derivatives129. 
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Figure 1.11. A 2D interaction model of the CDK1 ligand. The docking pose of the inhibitor 
shows hydrogen bonds and π-π stacking with the amino acid residues of CDK1. 
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Figure 1.12. A CDK1 inhibitor bound into the CDK1 ATP binding site. The binding site of 
CDK1 (homology model) is shown as a surface surrounding the CDK1 ligand (shown as sticks 
with white carbon atoms). The secondary structure is colored by residue.  
 
1.3.2. CDK5 as a kinase target for AD 
Substantial progress has been made regarding understanding the contribution of CDK5 to 
the pathophysiology of AD130, 131. Studies using animal models of AD largely confirmed that 
CDK5 deregulation contributes to neuronal loss in the disease. Indeed, studies revealed that 
selective inhibition of CDK5–p25 (the truncated activator, Figure 1.14) reduces the Aβ-induced 
neuronal loss in cortical neurons132, 133. CDK5 is implicated not only in tau hyperphosphorylation 
but also in regulating the generation of Aβ134. CDK5 activation increases Aβ production and 
accumulation in the cell body and neurites, while CDK5 inhibition attenuates Aβ production in 
transgenic mice overexpressing p25134, 135.  
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Further studies revealed that CDK5 phosphorylates STAT3 and enhances its 
transcriptional activity, resulting in elevated transcription of BACE1, thereby increasing Aβ 
generation120, 136. In accordance with the identification of CDK5 as a tau kinase, knockdown of 
CDK5 decreases tau phosphorylation and NFT formation in triple-transgenic Alzheimer’s 
mice137, 138. Furthermore, Aβ-induced activation of CDK5 is suggested to mediate local 
phosphorylation of tau, leading to the dissociation of tau from microtubules139, 140. CDK5 also 
facilitates tau phosphorylation by inhibiting phosphatase enzymes137. In addition, CDK5-
mediated phosphorylation of CRMP2141, another microtubule binding protein that is 
hyperphosphorylated in patients with AD, is particularly resistant to dephosphorylation. These 
findings together indicate that CDK5 may also enhance phosphorylation of microtubule binding 
proteins in AD by interfering with their dephosphorylation.  
 
 
Figure 1.14. The structure of CDK5 (dark green) in complex with its activator, p25 (light green), 
(PDB code 1UNG142). 
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 Several crystal structures of CDK5 have been released (Table 1.3) in complex with 
inhibitors illuminating the basic structural features of the enzyme and the ligand-enzyme 
interaction profile (Figures 1.15-1.16). 
 
Table 1.3. Examples of the released crystal structures of CDK5 and their cognate ligands.  
PDB Code Ligand Resolution (Å) 
1UNG142  2.30 
1UNH143, 144  2.35 
1UNL144  2.20 
3O0G145  1.95 
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Figure 1.15. The CDK5 ligand binds in the ATP pocket of the enzyme (PDB code 1UNG142). 
The protein is colored using residue color scheme.  
 
 
Figure 1.16. The 2D interaction model of the CDK5 ligand (PDB code 1UNG142). 
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1.3.3. GSK-3 as a kinase target for AD 
GSK-3 was originally discovered as a participant in glycogen metabolism, but also plays 
an important role in cell proliferation, apoptosis and immune response pathways146. GSK-3 is 
known to play key roles in the regulation of several cellular events and also in the 
phosphorylation of several protein substrates147. Phosphorylation at serine 21 (for the GSK-3α 
isoform) or at serine residues 9 and 389 (for the GSK-3β isoform) inhibits GSK-3 activity 
whereas phosphorylation at tyrosine 279 (for GSK-3α isoform) and at tyrosine 216 (for GSK-3β 
isoform) increases GSK-3 activity148. GSK-3 phosphorylation can be catalyzed by several 
protein kinases including cAMP-dependent protein kinase A (PKA) and protein kinase C 
(PKC)148. GSK-3 is also considered as a central switch in receiving signals for growth factors, 
insulin and amino acids149, 150. GSK-3 is known for its role in the determination of cell-fate 
during embryogenesis, phosphorylation of the WNT signaling-pathway and inhibition of gene-
expression by the degradation of beta-catenin151, 152. It also regulates axon-growth during brain 
development, neurogenesis and neuronal polarization153, 154. There is much evidence that 
demonstrates the role of GSK-3 in the pathophysiology of AD155. Studies show increased levels 
of GSK-3α and -3β in the frontal cortex of AD brains and accumulation of the same in the 
somatodendrites at all stages of neurodegeneration156, 157. The activation of GSK-3β as an early 
event is usually preceding and/or accompanying the NFTs’ formation158.  
Tau phosphorylation by GSK-3 occurs at 42 sites, 29 of which are found in the 
phosphorylated state in AD brains137, 159. Overexpression of GSK-3 in transgenic mice induces 
tau hyperphosphorylation and consequently neurodegeneration, and a GSK-3 inhibitor may 
reverse both processes160. Moreover, GSK-3 overexpression in cell lines causes apoptotic cell 
death, suggesting that tau phosphorylation by GSK-3 could be toxic161. The central role of GSK-
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3 in AD, specifically tau pathogenesis, was clearly established by exposing cultured rat 
hippocampal neurons to Aβ peptide, increasing GSK-3 level, tau phosphorylation and neuronal 
cell death162. 
In animal models, the increase of GSK-3 activity is involved in tau phosphorylation, 
memory impairment, inflammatory response, increased production of Aβ and reduced 
acetylcholine synthesis (a cholinergic deficit is observed in AD)163, 164. In AD patients, GSK-3 
co-localizes with NFTs and the active form of GSK-3 (phosphorylated at tyrosine 216) increases 
in the frontal cortex of AD brains115. Due to the increase in GSK-3 activity in AD brains and its 
involvement in the acceleration of tau pathology, GSK-3 seems to be a promising therapeutic 
target against tauopathies like AD. 
The structures of GSK-3β co-crystallized with several inhibitors have been solved by X-
ray crystallography. These structures encourage for the design of both novel and selective GSK-3 
inhibitors. However, the majority of the known GSK-3 inhibitors are ATP competitive and target 
the ATP binding site of GSK-3165. Several GSK-3 inhibitors can be extracted from the Protein 
Data Bank (PDB) (Table 1.4, Figures 1.17 and 1.18). 
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Table 1.4. Examples of the released crystal structures of GSK-3β and their cognate ligands. 
PDB Code Ligand Resolution (Å) 
1Q3D166  2.20 
1Q3W166  2.30 
1Q41167  2.10 
1Q5K168 
  1.94 
1R0E169  2.25 
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2JLD170  2.35 
2O5K171  3.20 
3DU8172  2.20 
3GB2173  2.40 
3I4B174  2.30 
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3L1S175  2.90 
3Q3B176  2.70 
3SD0177  2.70 
3ZDI178  2.64 
3ZRL179  2.48 
3ZRM179  2.49 
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4ACC180  2.21 
4ACD180  2.60 
4ACG180  2.60 
4ACH180  2.60 
 
           
Figure 1.17.  The GSK-3β inhibitor in complex with the enzyme (PDB code 4ACG180) 
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Figure 1.18. The 2D interaction model of the GSK-3β inhibitor (PDB code 4ACG180). The 
cognate ligand shows several hydrogen bonds, π-π stacking and hydrophobic contacts. 
 
1.3.4. PKC-ε as a kinase target for AD 
The term protein kinase C (PKC)181 refers to a serine/threonine family of phosphorylating 
enzymes that have significant roles in numerous cellular functions by transducing signals 
involved in short-term activities (ion fluxes, neurotransmitter release), mid-term processes 
(receptor modulation), as well as long-term processes (cell proliferation, synaptic remodeling 
and gene expression)182. According to sequence homology and sensitivity to activators, about 10 
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isoforms (determined by nine different genes) have been described, and may be grouped into 3 
distinct classes: (1) calcium-dependent or classical; (2) calcium-independent or novel nPKCs; 
and finally (3) atypical aPKCs183. The general construction of the different PKCs includes 
preserved domains (C1–C4) separated by variable sequences (V1–V5). C1 and C2 represent the 
regulatory portion of each enzyme with which the activators bind, while C3 and C4 form the 
catalytic region required for both the substrate binding and the kinase activity183, 184. There is a 
high degree of shared homology among the kinases particularly at the catalytic domain.  
The C1 domain bears one (in atypical) or two (in conventional and novel) cysteine-rich 
regions, located close to the amino-terminal region, that characterize the docking sites for 
phosphatidylserine (PS) and the known physiological activator diacylglycerol (DAG) as well as 
for the phorbol esters, which activate all the different PKCs, with the exception of the atypical 
isoforms (that are activated by phosphatidylinositol-3,4,5-trisphosphate)185.  
The C2 region contains the Ca2+ binding-site and is present in both the conventional and 
the novel isoenzymes186, 187. However, the nPKCs are not responsive to Ca2+ because of the 
absence in the C2-like domain of amino acids residues essential for the Ca2+ binding: recruitment 
to membrane is dependent on a C1 region with higher affinity for phospholipids (in comparison 
with cPKCs)188. Lastly, C3 contains the ATP binding portion (Figure 1. 19), while C4 comprises 
the substrate docking sequence189. 
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Figure 1.19. Cartoon representation of the 3D model of the kinase domain of PKC-ε. 
 
It has been shown that PKC-ε reduces Aβ levels in vitro and in vivo190, 191. PKC-ε acts on 
the stimulation of Aβ degradation in the brains of PKC-ε transgenic mice that express 
amyloidogenic variants of human APP190, 191. The activation of the α-secretase-mediated 
cleavage of APP may be conducted directly by PKC isozymes α and ε or indirectly through PKC 
activation of ERK1/2, or both190, 191.  
On the other hand, Aβ can inactivate PKC: Aβ contains a putative PKC pseudosubstrate 
site (Aβ28–30), which is critical for Aβ–PKC direct interaction. Aβ1–40, at high concentrations, 
also reduced PKC-mediated phosphorylation of several soluble brain proteins in a liposome 
system. Addition of Aβ1–40 peptides to cultured B103 cells reduced the activated form of PKC-
ε192, 193. This also suppressed phorbol ester-mediated membrane translocation of PKC-ε without 
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changing its expression level, demonstrating that activation of intracellular PKC-ε is reduced by 
treatment with Aβ peptides. 
Decreased PKC-ε activation leads to the following194: 
(1) Deactivation of HuD, an mRNA binding protein important in the stability and genetic 
expression of various mRNAs that play a role in neuronal plasticity of the CNS. 
(2) Decreased mRNA stability of NEP (the major physiological Aβ-peptide degrading 
enzyme in the brain), allowing Aβ accumulation and disease progression.  
It was observed in AD transgenic mice that activation of PKC-ε195 could prevent 
synaptotoxic Aβ-oligomer elevation, synaptic damage, cognitive insufficiencies, and amyloid 
plaque growth. Additionally, the treatment of AD mice and an aged rat model with bryostatin, a 
selective PKC-ε activator (Figure 1.20), can dramatically reduce levels of Aβ, regenerate 
neurotrophic activity and synapses, and improve cognitive function190, 196, 197. Furthermore, a 
severe AD patient who was confirmed to have a known genetic variant of PSEN1, showed 
promising benefits with bryostatin treatment of the kind not previously shown with any other 
treatment(s)198. Thus, isoform-specific PKC activators are highly desirable as potential anti-
Alzheimer’s drugs.  
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Figure 1.20. The chemical structure of bryostatin (left) and its proposed binding pose with PKC-
ε domain C1B. 
  
1.3.5. PERK as a kinase target for AD 
PERK, also known by names such as PEK or EIF2AK3, is predominantly activated in the 
endoplasmic reticulum (ER) by means of misfolded protein-accumulation199-201. This 
phenomenon is called ER stress202. The synthesis of new polypeptides is blocked by PERK 
through the phosphorylation of eIF2α, thereby hindering the entry of the nascent polypeptides 
into the lumen of the ER. This enhances the time necessary for the ER to refold and dispose of 
the terminally misfolded proteins that are important elements for the cell’s unfolded protein 
response (UPR), thereby restoring the ER homeostasis202.  
Normally, UPR should be ended after resolving the ER stress203. However, in case of AD, 
the neuronal cells in the temporal cortex and the hippocampus continue to produce misfolded 
proteins, which keeps activating the UPR, preventing its programmed turn off35, 204. The role of 
PERK has gained much importance in recent years based on its implications in pathologies like 
diabetes, ischemia, and cancer205. PERK is an ER transmembrane-protein with its N-terminal 
region located inside the lumen of the ER while the C-terminal is cytosolic206. The N-terminal 
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region interacts with other proteins and is important for regulation, association and binding to the 
immunoglobulin binding protein (BiP), an ER chaperone207, 208. The C-terminal region includes 
the kinase domain and the autophosphorylation sites207. The specific trigger for PERK activation 
remains unclear, with self-dimerization being considered to be critical.  PERK is bound to BiP in 
its inactive state with misfolded proteins competing with PERK in the ER lumen for BiP 
binding207, 208. The dissociation of BiP from PERK is known to be caused by the accumulation of 
misfolded proteins, thereby leading to dimerization. 
The stimulation of UPR signaling is known to induce tau phosphorylation209. The 
phosphorylation of the UPR stress-sensor PERK and its downstream substrate eIF2α are 
observed in AD brains209. Also, activation of the related kinase PKR correlates to the ER stress-
levels in AD brains. In vitro studies suggested an interesting ER stress connection between tau 
hyperphosphorylation and Aβ-mediated neurotoxicity210. Interestingly, neurons with active 
PERK are known to express active GSK-3β in the affected neurons of the AD brain211. The risk 
factors associated with the development of sporadic tauopathies include genetic variants related 
to single nucleotide polymorphisms in the PERK gene (Figure 1.21).  
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Figure 1.21. The eIF2α kinase (PERK) becomes activated in response to accumulation of 
amyloid and tau aggregates212. Persistent eIF2α phosphorylation through aberrant activation of 
this kinase in AD causes the inhibition of overall translation, while it triggers gene-specific 
translation of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is responsible 
for the generation of Aβ. PERK also activates the activating transcription factor 4 (ATF-4), 
which in turn suppresses the cAMP response element-binding protein (CREB). The CREB 
proteins in neurons are involved in the formation of long-term memories. Figure reproduced with 
permission from Masuo Ohno (2014), Roles of eIF2α kinases in the pathogenesis of Alzheimer’s 
disease. Front. Mol. Neurosci. 7: 22. doi: 10.3389/fnmol.2014.00022. 
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Recently, it has been shown that the UPR is activated in AD brain, with detection of in-
creased levels of BiP and phosphorylated PERK in the temporal cortex and the hippocampus. 
Screening for PERK inhibitors led to the identification of the compound GSK2606414213 with 
IC50 of 3.2 nM and it was co-crystallized with the PERK kinase do-main (PDB ID, 4G31213). 
Other reported PERK inhibitors that have been co-crystallized with the PERK kinase domain are 
shown in Table 1.5 and Figures 1.22 and 1.23. Identification of the role of the UPR/PERK/eIF2α 
signaling pathway in the pathophysiology of neurodegenerative diseases led to the emergence of 
PERK as a novel therapeutic target for AD. 
 
Table 1.5. Examples of the released crystal structures of PERK and their cognate ligands. 
PDB code Ligand Resolution (Å) 
 
4G31213 
 2.28 
 
4G34213 
 2.72 
 
4M7I214 
 2.34 
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4X7H214 
 2.00 
 
4X7J214 
 2.32 
 
4X7K214 
 1.80 
 
4X7L214 
 1.90 
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4X7O214 
 2.65 
 
GSK2606414213 was found to be neuroprotective during testing in mice. Mice have been 
cured from Creutzfeldt–Jakob disease upon treatment with GSK2606414. Because the 
mechanism of neuronal death is the same in both diseases, Creutzfeldt–Jakob disease and AD, 
the neuroprotective ability of GSK2606414 is a strong motivation to search for new PERK 
inhibitors. 
 
 
 
Figure 1.22. The binding pose of PERK–GSK2606414213, 215. The receptor site is shown as 
surface and the protein secondary structure is colored using residue color scheme. The amino 
acid residues involved in interaction with the ligand are shown as lines. 
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Figure 1.23. PERK–GSK2606414213 (1-[5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-
yl]-2,3-dihydro-1H-indol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone) interaction profile213. 
This schematic diagram (not to scale) shows that the trifluoromethyl group forms hydrophobic 
interactions with several hydrophobic amino residues (green spheres); the carbonyl group forms 
a hydrogen bond with a structural water molecule; the purine ring forms a π-π interaction with 
the aromatic ring of F943; and the amino group and the pyrimidine nitrogen form hydrogen 
bonds with Q888 and C890, respectively.  
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1.4. Summary  
The demanding need for new disease-modifying drugs of AD requires development of 
new treatment strategies and finding alternative drug targets. Several kinases are strongly 
involved in AD progression through tau phosphorylation and the amyloid cascade. One 
therapeutic goal is to inhibit kinases that mediate the phosphorylation of amino acid residues 
found to be hyperphosphorylated in Alzheimer’s brain. These kinases include CDK1, CDK5 and 
GSK-3 (α and β). AD intervention can also be accomplished through reduction of Aβ levels, 
which is possible through development of PKC-ε activators. PKC-ε activators could help 
reinstate NEP levels and activity in the AD brain, leading to a substantial decrease of toxic Aβ 
levels, and therefore re-establish synaptogenesis and cognitive function. Recently, ER stress has 
been agreed upon as an important factor in neurodegenerative diseases including AD. Increasing 
the number of unfolded proteins in the ER causes release of ER chaperones from the stress-
sensing domain of PERK.  PERK phosphorylates eIF2α, transforming eIF2α to an inhibitor of 
the ribosome translation initiation complex, and consequently shutting down protein production, 
leading to neuronal cell death. We ultimately aim to develop new AD drugs by targeting some of 
the kinases significantly involved in the pathophysiology of AD. In Chapter 2, we describe the 
construction of 3D models of CDK1, GSK-3α and PKC-ε. In Chapter 3, we present structural 
analysis and thermodynamic calculations of CDK1, CDK5, GSK-3 and PERK. In Chapter 4, we 
show the study of protein-ligand interactions using molecular dynamics simulations. Finally, 
Chapter 5 will demonstrate three virtual screening protocols to find new inhibitors/ activators of 
these protein kinases.  
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                                      Manal A. Nael and Robert J. Doerksen 
CHAPTER 2. GENERATION OF 3D MODELS OF THE KINASE DOMAINS OF CDK1, 
GSK-3α, AND PKC-ε 
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2.1. Introduction 
 The standard homology modeling procedure216 consists of seven main tasks including; 
recognition of template protein(s) which is/are highly homologous to the query sequence, 
sequence alignment, backbone generation, loop modeling, side chain construction, structure 
optimization and validation. We used Prime module of the Schrödinger suite217-219 to construct 
and refine the 3D models. The secondary structure and the relative solvent accessibility of the 
query sequence were predicted by using SSPro and PSIPRED modules220, 221. We then used 
3DLigandSite to define the amino acid residues in the ATP binding site222. The information from 
structurally similar protein was used predict the active sites. 	
2.1.1. Homology modeling methodology 
 The amino acid sequence of human CDK1 was obtained from The Universal Protein 
Resource (UniProt) (http://www.uniprot.org)223, 224. To define the most homologous protein 
structure to the query sequence all the experimentally released protein structures in the PDB 
repository225 (http://www.rcsb.org) were searched using the Prime [Basic Local Alignment 
Search Tool226 (BLAST)] homology search tool. To ensure complete search, we used the PSI-
BLAST227 (Position-Specific Iterative BLAST) as the search tool, the non-redundant database 
from the National Center for Biotechnology Information228 (NCBI NR) as the search database, 
and the BLOcks SUbstitution Matrix229 (BLOSUM62, that is built using sequences with no more 
than 62% similarity) as the similarity matrix. All homologous experimental protein structures 
were retrieved and ranked based on their similarity to the query sequence.  
 We used the search option for globally conserved residues to identify the protein family 
to which the query sequence belongs. We ran the HMMER program230 on the Pfam database231 
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to generate a Hidden Markov Model (HMM) from a multiple sequence alignment and identify 
the query family based on the Expectation value (E-value) and provide information about which 
residues are conserved in the consensus sequence. 
 The secondary structure and the relative solvent accessibility of the query sequence 
were predicted by using the SSPro and PSIPRED programs220, 221. We aligned the template and 
query sequences using the ClustalW tool232. This was done through a position-specific 
substitutional matrix (PSSM) for the query sequence that is derived from the PSI-BLAST result 
and is used to match the template sequence217, 218. We constructed a composite secondary 
structure for the query sequence from multiple predictions in order to minimize the possible 
inaccuracy of relying on a single secondary structure. The composite secondary structure 
prediction (SSP) was aligned to the secondary structure assignment (SSA) of the template. Based 
on the globally conserved residues that were defined in the previous step, we made necessary 
alignment edits using the Single Template Alignment (STA) program to generate an accurate 
alignment between proteins with medium to high sequence identity (20-90%)233.   We used the 
composite/chimera model builder of Prime to use multiple templates to construct 10 models for 
each target sequence. We retained all rotamers for conserved residues, and we optimized the side 
chains by minimizing all residues that were not derived from the templates. We allowed the 
option of omitting the structural discontinuities if there is a gap in the template (insertion) of 
more than 20 amino acids.  We used the loop refinement option to correct atomic charges and 
bond orders, and to fix disparities that existed between the sequence and the structure. The 
geometry of the final 3D model was then optimized by running extensive energy minimization 
using the OPLS2005 force field234 and with the Variable-Dielectric Surface Generalized Born 
model235 (VSGB), as a solvation model. The root mean square (RMS) gradient for convergence 
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was set to 0.001 kcal/mol/Å. The protein structure quality was checked using the Procheck 
software236. We used the 3DLigandSite to predict the possible ligand cavity and the amino acid 
residues involved in ATP binding. 3DLigandSite222 is a web server which succeeded in 
predicting the ligand binding pockets of several proteins in the eighth round of the Critical 
Assessment of techniques for protein Structure Prediction222 (CASP-8). The information from 
similar structures was used to predict these sites. Similar protein structures were aligned to the 
model to allow for placing the ligands in the 3D model. Other structural motifs were predicted 
based on the protein family information. 
 
2.1.2. Results and discussion 
 CDK1 is found in two isoforms123: 1 and 2. Isoform 2 differs from isoform 1 in that it 
is missing the residues from 107-163. Isoform 2 is known to exist in breast cancer tissues and is 
reported to accumulate following the G1 and S phases of the cell cycle. Isoform 1 is the 
canonical sequence and it is composed of 297 amino acids: 
 MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM	
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 The PSI-BLAST search for sequence homologs retrieved all similar experimental 
structures and we selected three templates (1UNL143, CDK5; 1GZ8237, CDK2 and 1OB3238, P. 
falciparum CDK5) based on percent identity to our target sequence (Table 2.1). 
 
Table 2.1. Template structures used in modeling CDK1. 
Template (PDB Code) Identities Positives Gaps Pfam 
1GZ8237 64% 78% 3% 27/25 
1OB3238 60% 73% 1% 31/25 
1UNL143 56% 72% 1% 28/25 
 
 The three templates were aligned to the query sequence (Figure 2.1). Required 
alignment edits were made based on the information retrieved from the Pfam of globally 
conserved residues. SSPro was used in this step to assign the secondary structures of the template 
and target proteins. CDK-1, as expected, contains a protein kinase domain with very high 
expectation value (E-value = 1.1e-78). We generated HMMER/Pfam consensus sequence (see 
new-0_pfam in Figure 2.1) using the globally conserved residues and the identified protein 
family of the query sequence. Different symbols are used in Pfam alignment to refer to the 
different matching states such as capital letters are used for highly conserved positions, 
lowercase letters for residues that match the HMM, and + for residues that are conserved 
according to HMM. We used the coloring scheme option to show residue matching as in Figure 
2.1, taking into consideration that template residues are only colored if they match the query, 
while query residues are only colored if they match residues in one or more templates. The 
matching residues are colored according to residue property: gray if not matching, dark green for 
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amino acid residues Ala, Phe, Ile, Leu, Met, Val and Tyr, blue for Lys and Arg, light blue for 
Asn and Gln, red for Asp and Glu, yellow for Cys, purple for Gly, cyan for His, orange for Pro, 
pink for Ser and Thr, and green for Trp. The alignment of the query sequence and CDK5 (PDB 
code 1UNL) is shown in Figure 2.2. We constructed 10 models for CDK1 and we found the 
loops that were modeled as flexible to be far from the ligand binding site (Figure 2.3).  
	
Figure 2.1. Sequence alignment and secondary structure assignment of the query (-new-0) and 
template structures. The globally conserved amino acid residues (new-0-pfam), and the template 
proteins [1GZ8 (human CDK2), IUNL (human CDK5), and 1OB3 (P. falciparum CDK5)] are 
colored based on matching. SSPro was used to assign the secondary structures. 
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Figure 2.2. Alignment of the CDK1 sequence (Query) with CDK5 (PDB ID: 1UNL as 
Template) showing 1: predicted secondary structures, 2: query sequence, 3: temple sequence, 4: 
template known secondary structure, 5: template predicted secondary structure. Dark brown 
blocks show insertions relative to the template. Orange blocks show deletions relative to the 
template. Red squares around particular template sequences are for known catalytic sites. 
Secondary structure information is represented using G for 3-turn helix (310 helix), I for 5-turn 
helix (π helix), T for hydrogen bonded turn, B for residue in isolated β-bridge, and S for bend. 
Identical residues are highlighted with a grey background. 
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Figure 2.3. Cartoon representation of a CDK1 model using yellow for the α-helices, red for the 
β-sheets and green for the loops. The loops that are modeled to be flexible are shown in boxes, 
and are found far from the ligand binding site. CDK1 is bilobial with the N-lobe mostly 
composed of β-sheets and the C lobe mostly α-helices. The binding pocket is at the intersection 
of the two lobes. 
 
 We calculated the hydrophobic and hydrophilic properties of the models (Figure 2.4) 
using the Protein Patch Analyzer239 to build protein surface patches to predict the protein sites 
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that are highly prone to promote aggregations. This application aids in understanding protein 
properties and making decision in mutation studies. The hydrophobic/hydrophilic patches were 
determined using a van der Waals solvent accessible interaction surface. To calculate the 
interaction surface, a lattice is considered and a 0-potential contour is prepared of the van der 
Waals potential of a probe water oxygen atom with each residue. The positions at which the van 
der Waals energy of the oxygen atom probe is positive are those at the interior of the 0-potential 
surface and the exterior of the 0-potential contains the negative interaction energy. This is 
calculated as follow: 																																𝑣 𝑥 = 	 𝐴& 𝑥 − 𝑥& ()* − 𝐵& 𝑥 − 𝑥& (,&  
where v(x) is the van der Waals potential, Ai and Bi are the OPLSA-AA240 van der Waals 
parameters with a water oxygen used as a probe. The interaction surface is significant at the 
points which are in close contact to the water oxygen, and therefore this calculation is similar to 
calculating the solvent accessible surface of a molecule. We calculated three classes of patches 
by considering the electrostatic and hydrophobic potential calculations. Thus we were able to 
define the negative and positive hydrophobic patches on the protein. The positive and negative 
patches are associated with positive and negative electrostatic potentials, respectively. The 
hydrophobic potential241 is calculated using the following equation: 																																															𝐸./0 = 	 12	3	(52)2 3(52)2  
where Exyz is the potential, fi is the contribution for atom i and g(di)242 is the Fermi-type distance 
function: 
																																								𝑔 𝑑& = 	 9:;<=>?@AA	BC9:;(<2:<=>?@AA)BC 
with a proximity distance (dcutoff) of 2.5 Å and α = 1.5. 
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Figure 2.4. The aggregation-prone regions (APRs) in the CDK1 model. The CDK1 model is 
shown using cartoon representation with yellow for β-sheets and red for α-helices. The number 
of hydrophobic patches (hyd) is one and that patch is colored using a green surface. We noted 
two negative patches colored red and eight positive patches colored blue. 
 
 The aggregation-prone regions (APRs) in proteins are characterized by high surface 
exposure and strong interaction potential, ARPs become surface exposed upon conformational 
transition to facilitate intermolecular interaction. The interaction potential is calculated using the 
previous equations. The surface exposure is calculated by rolling a protein probe with a 5.0-Å 
radius over the target protein. The properties associated with each patch are calculated (Table 
2.2). Because different residues have different roles in the known forms of protein aggregation, 
we checked all residues that are represented in the patches. Positions exposed to arginine 
residues are prone to deamidation or glycosylation. Tyrosine residues which are surface exposed 
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can form covalent species. The highly surface-exposed arginine residues that we found in CDK1 
are Arg50, Arg59, Arg75, Arg122, Arg123, Arg151, Arg158 and Arg180. There is no amino 
acid residue we can consider as a candidate for glycosylation in close proximity to these arginine 
residues, while Gln98 can undergo deamidation. Lys296 was also found to be surface exposed. 
 
Table 2.2. Properties of the protein patches. 
ID Type Area %ASA Max E Avg E N O 
1 hyd 135.11 2.50 0.31 0.13  2 
2 −  485.10 8.99 89.20 52.56  23 
3 −  57.63 1.07 70.91 46.00   
4 + 134.24 2.49 145.42 82.69 5  
5 + 77.80 1.44 109.59 68.06 2  
6 + 72.34 1.34 117.85 79.60 2  
7 + 67.00 1.24 124.63 74.47 2 1 
8 + 63.56 1.18 167.39 86.15 1  
9 + 62.28 1.15 125.60 74.15 2 1 
10 + 52.52 0.97 116.48 74.33 1  
11 + 52.21 0.97 113.52 77.47 2  
hyd for hydrophobic, − for negative and + for positive patch types.  Area: Water-accessible 
surface area in square Ångstroms; % ASA: Percentage of patch to total protein surface area; 
Max, Avg: Maximum/average patch potential values (kcal/mol); N, S, O: Number of highly 
accessible nitrogen, sulphur and oxygen atoms; and W: Number of highly accessible tryptophan 
residues. 
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 The following amino acid residues are associated with the prospective patches. The 
hydrophobic patch implicates Gln98, Tyr99 and Met100. The negative patch (2) is associated 
with Leu37, Glu38, Ser39, Glu40, Glu41, Glu42, Val44, Ser46, and Ser74. Negative patch 3 
contains Gly97, Met100, Asp101, and Ser102. Positive patch 4 consists of Arg123, Arg180 and 
Ser182. Patch 5 is associated with Arg122, patch 6 with Arg61, Pro61 and Ly143, patch 7 with 
Gln98, Met100 and Lys296, patch 8 with Leu37 and Arg75.  Patch 9 contains Ser46 and Arg50. 
Patch 10 associated with Arg151 and patch 11 with Arg158. 
 We verified the quality of the models to consider more refinement for any distortion. 
The quality of a protein structure is estimated by comparing all residue values with that reported 
proteins in the PDB. The model was checked for allowed and disallowed dihedral angles, main 
chain parameters, residue properties, bond lengths, planarity and distorted geometry. We used 
the Ramachandran plot243 to check the dihedral angles. Generally, glycine residues are plotted as 
triangles; proline residues as squares and all other amino acid residues are plotted as circles.  
 All amino acids were found in the allowed regions of the Ramachandran plot (Figure 
2.5), 94.2% of the amino acids are in the core regions and 5.7% in the generously allowed ones. 
Chi1-chi2 angles, which describe the dihedral angles of the side chains, are in the acceptable 
limits for each amino acid. The main parameters including peptide bond planarity, bad non-
bonded interactions, Calpha tetrahedral distortion, main-chain hydrogen bond energy and overall 
G-factor, showed comparable results to well-refined structures at resolution of 2.5 Å.   
 The side chain parameters including standard deviation of the chi-1 gauche minus 
torsion angles, standard deviation of the chi-1 trans torsion angles, standard deviation of the chi-
1 gauche plus torsion angles, pooled standard deviation of all chi-1 torsion angles, standard 
deviation of the chi-2 trans torsion angles, are also comparable to well-refined structures at 
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resolution of 2.5 Å. Residue properties show a maximum deviation of 2.0 Å with no bad 
contacts. In general, the 3D models were found to be suitable to be used in our further 
calculations. 
 
 
Figure 2.5. The Ramachandran plot of the CDK1 model. Glycine amino acid residues are plotted 
as triangles, proline residues are shown as squares and all other amino acid residues are plotted 
as circles. 
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 In order to start the structure based drug design process we need to predict the ligand 
binding sites. We used 3DLigandSite222 to determine the amino acid residues included in the 
ligand pocket as well as the ATP binding site. The information from structurally similar 
experimental protein structures was used to guide predicting these sites. Similar protein 
structures were aligned to the model to allow for placing the ligands in the 3D model (Figures 
2.6 and 2.7).  Table 2.3 shows the protein (PDB) files that were used in the prediction of the 
ligand binding pockets. 
 
Figure 2.6. Similar protein structures (PDB codes: 1AQ1244, 1J1C245, 2B9J246, 2B9H246, 2B9I246, 
1HCK247, 1B38248, 1B39248, 1FQ1249, 1QMZ250, 1GY3250, 2CCI251, 2CJM252, 1R3C253, 3BLQ166, 
1PYX167, 1LP4254, 3GC0255, 1JST256, and 1UA2257) aligned with CDK1 model. The protein 
structures are shown as cartoon with distinct color for each protein. 
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Figure 2.7. Prediction of the ligand binding sites in the CDK1 model. All ligands are extracted 
from other known experimentally defined proteins. Ligands are shown as sticks, metal ions as 
green spheres. The amino acid residues which are surrounding the ligand binding pockets are 
shown in blue and the other parts of the protein are shown in grey cartoon. 
 
Table 2.3. The ligands and PDB files used to predict the active site of CDK1 model. 
 
Ligand  Count Source structures 
STU 1 1AQ1 
ADP 4 1J1C, 2B9J, 2B9I, 2B9H 
MG 18 1HCK, 1B39, 1B38, 1FQ1, 1QMZ, 
1GY3, 2CCI, 2CJM, 1R3C, 3BLQ,  
1J1C, 1PYX, 2B9J, 2B9I, 2B9H,  
1LP4 
AMP 1 3GC0 
ATP 13 1HCK, 1B39, 1B38, 1FQ1, 2CCH,  
1QMZ, 1FIN, 1GY3, 2CCI, 1JST,  
2CJM, 1UA2, 3BLQ 
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 Table 2.4 illustrates the amino acid residues that are associated with the ligand binding 
sites. Figure 2.8 shows the plausible ligand-binding pocket of CDK1 model. Others structural 
motifs were predicted based on the protein family information. 
 
Table 2.4. The amino acid residues included in the active site of CDK1 model.  
Residue Amino acid Contacts* Average distance* 
10 ILE 19 0.17 
12 GLU 18 0.22 
13 GLY 20 0.00 
14 THR 20 0.04 
15 TYR 17 0.05 
16 GLY 17 0.11 
18 VAL 19 0.01 
31 ALA 19 0.03 
33 LYS 19 0.01 
64 VAL 13 0.46 
80 PHE 18 0.20 
81 GLU 19 0.00 
82 PHE 19 0.00 
83 LEU 19 0.00 
86 ASP 14 0.32 
132 GLN 15 0.08 
133 ASN 21 0.28 
135 LEU 12 0.38 
146 ASP 22 0.11 
 
*Contacts to a residue are defined as the number of ligands (in the cluster of similar protein 
structures) that contact this specific residue. Average distance is the average of the distances 
between the residue and all ligands in the cluster. 
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Figure 2.8. The amino acid residues included in the active site of the CDK1 model. Left: The 
predicted ligand binding site of CDK1; amino acid residues surrounding the binding pocket are 
shown as cyan sticks, and the two most possible positions of Mg2+ ions based on binding site 
similarity with known protein structures are shown as green spheres. Right: surface 
representation of the binding pocket, in which AMP is shown as sticks. 
 
 Other sites are predicted from the protein family information including:  
• CDK/cyclin interface (Figure 2.9, green cartoon spots): L37, E42, G43, V44, S46, I49, 
R50, I52, S53, K56, E57, M71, V117, H120, S121, R122, R123, R151, A152, F153, 
I155, P156, Y160, T161, A273, S277, G278, K279  
• Polypeptide substrate binding site (Figure 2.9, cyan spots): R50, K88, D128, K130, 
L149, T161, E163, V164, V165, T166, W168, G206 and D207  
• Activation loop (A-loop) (Figure 2.9, pink spots): A145, D146, F147, G148, L149, 
A150, R151, A152, F153, G154, I155, P156, I157, R158, V159, Y160, T161, H162, 
E163, V164, V165, T166, L167 and W168  
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• ATP binding site (Figure 2.9, red spots): I10, G11, E12, G13, V18, A31, K33, V64, F80, 
E81, F82, L83, D86, K89, Q132, N133, L135 and D146  
• Active site (Figure 8): I10, G11, E12, G13, V18, A31, K33, R50, V64, F80, E81, F82, 
L83, D86, K88, K89, D128, K130, Q132, N133, L135, D146, L149, T161, E163, V164, 
V165, T166, W168, G206 and D207 
 
 
Figure 2.9. Different structural motifs of the CDK1 model: CDK/Cyclin interface is shown in 
green, the polypeptide binding site in cyan, the activation loop in pink and the ATP binding site 
in red. The protein is shown as white cartoon except for the described motifs. 
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2.2. Construction of 3D model of GSK-3α 
GSK-3α is a protein kinase, which phosphorylates glycogen synthase, beta-catenin, APC 
and AXIN1 and subsequently inactivates them258. Because it inhibits the activity of glycogen 
synthase by phosphorylation, GSK-3α helps in the insulin control of glycogen synthesis259. It is 
reported that GSK-3α regulates the processing and generation of the APP and APP-derived 
amyloid plaques that are found in AD259. GSK-3α phosphorylates the anti-apoptotic protein 
MCL1 and shows a prominent role in cell apoptosis. GSK-3α is activated when phosphorylated 
at Tyr279, and inhibited by phosphorylation at Ser21260. 
 
2.2.1. Homology modeling method 
 The amino acid sequence of human GSK-3α was downloaded from the UniProt 
database. We used the standard homology modeling procedure to construct the 3D models as we 
did in case of the generation of the CDK1. We validated the homology models using the protein 
quality option of Bioluminate261-263 and by Procheck software236. Ligand binding pockets and 
structural motifs were predicted by 3DLigandSite222 and protein family characteristics. 
 
2.2.2. Results and discussion 
 GSK-3α is found in a single isoform and consists of 483 amino acids and the kinase 
domain represents the amino acids from 119 to 403. The sequence of GSK-3α is shown below as 
obtained from the UniProt224 database and the kinase domain is highlighted in yellow. 
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MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLTNSS		
In this study, we are interested in constructing the 3D model of the sequence representing 
the kinase domain. We used the protein family information to find out the part of the sequence 
with the highest E-value for protein kinase family, and the amino acids highlighted in yellow 
were found to have an E-value of 2.38e-65. Because of the high sequence identity, the 
experimentally solved crystal structure of GSK-3β was used as a template in the homology 
modeling experiment. We modeled GSK-3α using GSK-3β (PDB ID: 4ACC180, Figure 2.10), 
which have a percent identity of 91% to GSK-3α and a resolution of 2.21 Å. While in a previous 
study in our lab264 it was modeled using 1Q41167 (80% identity and 2.1 Å resolution). We built 
10 models; in these models the variable loops were found to be located far from the expected 
ligand-binding pocket (Figure 2.11). We checked the models for quality as in case of CDK1 
model. The selected model was found to be acceptable to be used in subsequent calculations. All 
amino acids were found in the allowed regions of the Ramachandran plot (Figure 2.12), 92% of 
the amino acids are in the core regions and 8% in the generously allowed ones. Chi1-chi2 angles, 
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the main and the side chain parameters are comparable to well-refined structures at resolution of 
2.5 Å. Residue properties show a maximum deviation of 2.3 Å with no bad contacts. 
 
 
Figure 2.10. Alignment of the sequences of GSK-3α (Query) and GSK-3β (PDB ID: 4ACC as 
Template) showing 1: predicted secondary structures, 2: query sequence, 3: template sequence, 
4: template known secondary structure, 5: template predicted secondary structure. Brown blocks 
for insertions relative to template. Orange blocks for deletions relative to template. Red squares 
around particular template sequences for known catalytic sites. Secondary structure information 
is represented by G for 3-turn helix (310 helix), T for hydrogen bonded turn, B for residue in 
isolated β-bridge, and S for bend. Identical residues are highlighted with a grey background. 
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Figure 2.11. Cartoon representation of the GSK-3α model colored yellow for the α helices, red 
for the β sheets and green for the loops. The loops that are modeled to be flexible are shown in 
boxes, and are found far from the ligand binding sites (indicated by cyan arrow). GSK-3α is 
bilobial with N lobe mostly composed of β-sheets and the C lobe as α-helices. The binding 
pocket is at the intersection of the two lobes. 
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Figure 2.12. Ramachandran plot of the GSK-3α model. Glycine amino acid residues are plotted 
as triangles, proline residues are shown as squares and all other amino acid residues are plotted 
as circles. 
 
 We identified the hydrophobic and hydrophilic properties of the models (Figure 2.13) by 
applying the Protein Patch Analyzer utilizing a van der Waals solvent accessible interaction 
surface. The surface of negative and positive potential is calculated using oxygen atom probe. 
The properties associated with each patch are calculated (Table 2.5). Because different residues 
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have different roles in the known forms of protein aggregation, we checked all residues that are 
represented in the patches (Table 2.6). 
 
 
Figure 2.13. The aggregation-prone regions (APRs) in the GSK-3α model. GSK-3α is shown as 
cartoon representation colored yellow for the β-sheets and red for the α-helices. The 
hydrophobic patches are colored green, negative patches are colored red and positive patches are 
colored blue. 
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Table 2.5. Properties of the protein patches. 
Id   Type   Area   % ASA Max  Avg E N   O   S   
1   hyd   470.86   3.65   0.19   0.13   1     
2   hyd   373.84   2.90   0.19   0.13   1     
3   hyd   354.78   2.75   0.21   0.13   2     
4   hyd   171.26   1.33   0.20   0.12      
5   hyd   120.36   0.93   0.20   0.13      
6   hyd   102.57   0.79   0.21   0.13   1     
7   hyd   98.85   0.77   0.17   0.13   1     
8   hyd   58.67   0.45   0.20   0.13      
9   hyd   52.74   0.41   0.16   0.11      
10   hyd   50.71   0.39   0.14   0.09   1     
11   −  468.47   3.63   30.16   13.25   9     
12   −  315.55   2.44   29.15   12.68   3     
13   −  223.06   1.73   26.55   12.82   4     
14   −  185.65   1.44   30.73   13.25   2     
15   −  174.82   1.35   28.42   10.91   2     
16   −  134.44   1.04   28.98   12.75   1   3    
17   −  125.21   0.97   28.19   12.80   3     
18   −  107.44   0.83   27.79   11.77   1     
19   −  99.17   0.77   16.24   8.65      
20   −  88.20   0.68   28.00   14.02   2     
21   −  87.79   0.68   30.81   13.63      
22   −  74.94   0.58   25.59   9.48      
23   −  74.15   0.57   27.71   15.88   2     
24   −  67.16   0.52   13.48   6.98   2   1    
25   −  65.52   0.51   16.50   8.96      
26   −  64.60   0.50   19.41   8.83   1   1    
27   −  63.18   0.49   13.74   7.91   1   1    
28   −  52.39   0.41   23.86   11.07   1   2    
29   +  214.20   1.66   39.33   13.60   3     
30   +  191.97   1.49   42.17   17.90   5   1    
31   +  157.20   1.22   41.37   16.44   1     
32   +  152.59   1.18   36.88   12.81   4     
33   +  130.02   1.01   33.73   12.17   2     
34   +  126.43   0.98   36.70   13.62   3     
35   +  109.44   0.85   29.59   9.75      
36   +  101.64   0.79   35.52   12.47   1   1    
37   +  100.69   0.78   37.11   14.79   2   1   1   
38   +  93.84   0.73   36.38   15.12   2     
39   +  91.38   0.71   34.92   15.23   2     
40   +  85.64   0.66   36.92   12.46   2     
41   +  80.22   0.62   37.70   14.24      
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42   +  76.00   0.59   38.26   16.89   1     
43   +  74.32   0.58   37.69   13.70   1     
44   +  74.14   0.57   34.99   12.02   3   1    
45   +  73.39   0.57   35.53   13.63   1     
46   +  70.40   0.55   38.83   15.57   1     
47   +  64.78   0.50   39.15   15.72      
48   +  62.78   0.49   37.78   16.12   1     
49   +  60.72   0.47   33.87   11.63   2     
50   +  59.67   0.46   37.85   17.36   1     
51   +  58.91   0.46   35.42   13.94   2     
52   +  57.20   0.44   35.58   14.93   1     
53   +  56.23   0.44   37.32   17.55   1     
54   +  52.85   0.41   34.26   14.30   1     
hyd for hydrophobic, − for negative and + for positive patch types.  Area: Water-accessible 
surface area in square Ångstroms; % ASA: Percentage of patch to total protein surface area; 
Max, Avg: Maximum/average patch potential values (kcal/mol); N, S, O: Number of highly 
accessible nitrogen, sulphur and oxygen atoms; and W: Number of highly accessible tryptophan 
residues. 
 
Table 2.6. Residues associated with the respective patches. 
ID Type Residues 
  1  hyd  Ala139  
Leu101  
Val105  
Ala94  
Leu26  
Val87  
Glu82  
Leu96  
Tyr102  
Phe91  
Pro136  
Tyr106  
His90  
Pro81  
Tyr79  
Lys104 
Pro99  
2  hyd  Glu235  
Lys216  
Phe174  
Lys211  
Phe236  
Pro239  
Phe238  
Val208  
Ile215  
Val212  
Ile241  
Tyr233  
3  hyd  Glu70  
Leu33  
Tyr1  
Phe61  
Arg58  
Tyr16  
Ile29  
Val14  
Tyr59  
Ile4  
Val27  
Tyr72  
Lys31  
Val6  
Leu20  
Val76  
4  hyd  Ala28  
Lys30  
Val55  
Cys144  
Leu133  
Val80  
Asp145  
Leu77  
Tyr79  
Phe12  
Met46  
Phe146  
Thr83  
Ile7  
Val15  
5  hyd  Phe60  Leu71  Tyr62     
6  hyd  Ile162  Val159  Tyr161     
7  hyd  Ala115  Cys280  Leu277  Arg112    
8  hyd  Phe38       
9  hyd  Lys248  Pro245      
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10  hyd  Lys128  Pro200  Pro203  Tyr166  Tyr167   
11  − Ala176  
Glu267  
Gln225  
Ser272  
Ala260  
Glu278  
Arg227  
Ser275  
Asp178  
Leu274  
Arg273  
Thr180  
Glu171  
Asp158  
Ser263  
Thr269  
Glu224  
Pro231  
Ser264  
Trp246  
Glu228  
Pro270  
Ser271  
Tyr179  
12  − Ala139  
Leu26  
Thr23  
Asp135  
Pro136  
Val105  
Asp137  
Pro81  
Val140  
Glu25  
Gln109  
Val80  
Glu78  
Arg58  
Tyr79  
Lys142  
Thr138  
13  − Asp205  
Pro200  
Val212  
Asp209  
Pro203  
Tyr166  
Glu213  
Gln199  
Glu204  
Arg165  
Ile201  
Ser206  
Lys216  
Val208  
14  − Ala281  
Lys104  
Glu257  
Pro256  
Glu278  
Ser283  
Phe284  Phe285  His282  
15  − Asp50  
Arg56  
His51  
Tyr116  
Lys48  Leu49  Leu57  Arg47  
16  − Asp69  Glu70  Lys67  Lys68  Leu33   
17  − Asp69  Glu66  Glu70  Lys67  Lys68  Ser64  
18  − Glu156  Gly155  Lys150  Gln151  Arg154  Val153  
19  − Phe250  
Pro256  
Ile259  
Arg53  
Lys248  
Ser252  
Lys251  
Thr247  
Leu197  
Thr254  
Pro255  
Val249  
20  − Glu235  Phe236  Asn232  Pro231  Thr234   
21  − Asp126  
Ser148 
Asp145  Lys128  Lys30  Asn131  Gln130  
22  − Ala88  
Thr92  
Glu194  
Tyr85  
Gly198  Pro129  Pro200  Arg89  
23  − Glu22       
24  − Gly121  His118  Gln120  Gln151  Ser119   
25  − Asp35  Phe38  Lys36  Gln34  Arg37   
26  − Glu82  Pro81  Arg86  Val87  Tyr79   
27  − Phe12  Gly10  Gly13  Asn9  Ser11   
28  − Asp3  Arg19  Thr2     
29  +  Phe38  
Gln4  
Phe60  
Arg41  
Lys39  
Ag47  
Leu43  Aspn9 Gln34  
30  +  His90  Lys93  Arg86  Arg89  Tyr85   
31  +  Ile162  Lys150  Arg125  Arg41  Ser148  Val159  
32  +  Leu26  Arg19  Arg24     
33  +  Cys52  Glu78  Lys142  Arg56  Arg58   
34  +  Lys251  Arg253  Ser252  Thr254    
35  +  Ile173  
Ser164  
Lys128  
Tyr161  
Gln130  Gln210  Arg165  Arg168  
36  +  Glu66  Gly65  Lys31  Ser63  Ser64  Tyr16  
37  +  Cys52  His51  Arg112  Tyr108    
38  +  Arg154       
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39  +  Arg223       
40  +  Ile45  Lys48  Gln151  Gln44    
41  +  Lys251  Leu96  Thr97     
42  +  Ala243  Lys242      
43  +  Asp3  Lys  Pro81  Gln17    
44  +  Arg165  Tyr166      
45  +  Glu70  Lys36  Leu71     
46  +  Lys95  Thr92      
47  +  Ala21  Glu22  Leu20  Thr23  Tyr1   
48  +  His244  Lys248  Pro245     
49  +  Phe38  Arg37      
50  +  Arg237       
51  +  Arg227       
52  +  Phe284  Ile100  Lys104  Leu101  Pro99   
53  +  Lys68       
54  +  Lys67  Leu33      
 
 
The patch analyzer did not show any surface exposed tryptophan residues. There are 
several arginine residues are found to be highly surface exposed including Arg112, Arg227, 
Arg165, Arg47, Arg56, Arg154, Arg253, Arg89, Arg37, Arg86, Arg19, Arg41, Arg24 and 
Arg223. The residue Asn9 is expected to be a candidate for glycosylation, while Gln151 and 
Gln120 are considered sites for deamination. Several lysine residues are also found to be highly 
surface exposed including Lys104, Lys31, Lys248, Lys48, Lys67, Lys68, Lys36, Lys39, Lys93, 
Lys242, Lys5, Lys95 and Lys237. There is no exposed tyrosine residues or other residues with 
exposed oxygen atoms.  
The plausible location and the amino acid residues surrounding the ligand-binding pocket 
and ATP binding site were identified using 3DLigandSite. We used the information from the 
structurally similar proteins. The protein structures were aligned using the 3D model as the 
reference of frame to place the ligands and predict the ligand-binding pocket (Figures 2.14 and 
2.15). A 23 protein structures (Table 2.7) were found to have similar binding sites, and the 
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coordinates of their ligands were transferred to the 3D model. The positions of Mg2+ in the 
binding site were calculated (Figure 2.16 and Table 2.8). 
 
 
Figure 2.14. Similar protein structures (PDB codes: 1Q3D166, 1J1C245, 1Q8Y265, 2B9J246, 
2B9H246, 2B9F246, 1DS5266, 1PYX167, 1DAY267, 1DAW267, 1LP4267, 1Q97265, 2CCI251, 1QMZ250, 
1GY3250, 1FQ1249, 1GOL268, 2JD5269 and 1JNK270) aligned with the GSK-3α model. The protein 
structures are shown as cartoon with distinct color for each protein. 
 
 
73 
 
Figure 2.15. A cartoon representation of the 3D model of GSK-3α showing the ligand binding 
sites. All ligands are extracted from other known experimentally defined proteins. Ligands are 
shown as sticks and metal ions as green spheres. The amino acid residues surrounding the ligand 
binding pockets are shown in blue and the other parts of the protein is shown as grey cartoon. 
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Table 2.7. The ligands and PDB files aligned with GSK-3α model to predict the active site. 
Ligand Count Source structures 
STU 1 1Q3D 
ADP 6 1J1C, 1Q8Y, 2B9J, 2B9H, 2B9F 
MG 23 1DS5, 1PYX, 1DAY, 1DAW, 1LP4, 1Q97, 1J1C, 2CCI, 
1QMZ, 1GY3, 1Q8Y, 1FQ1, 2B9J, 2B9H, 2B9F, 1GOL, 
2JD5, 1JNK 
AMP 1 1DS5 
ATP 9 2CCH, 1Q97, 2CCI, 1QMZ, 1GY3, 1FIN, 1JST, 1FQ1, 
1GOL 
               
 
Figure 2.16. The predicted active site of the GSK-3α model. Amino acid residues surrounding 
the binding pocket are shown as cyan sticks, and the possible positions of Mg2+ ions based on 
binding site similarity with know protein structures are shown as green spheres. 
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Table 2.8. The amino acid residues included in the active site of GSK-3α model.  
Residue Amino acid Contacts Average distance 
7 ILE 17 0.17 
12 PHE 17 0.00 
15 VAL 16 0.25 
28 ALA 16 0.02 
30 LYS 15 0.20 
55 VAL 14 0.37 
78 GLU 17 0.00 
79 TYR 17 0.00 
80 VAL 17 0.00 
83 THR 15 0.21 
130 GLN 16 0.09 
131 ASN 28 0.29 
133 LEU 17 0.20 
144 CYS 13 0.55 
145 ASP 33 0.23 
 
 
 Other binding sites and important motifs were predicted from alignment with known 
proteins using 3DLigandSite, and Conserved Domain Database search. These domains include: 
• Activation loop (A-loop) (Figure 2.18: green): C144, D145, F146, G147, S148, A149, 
K150, Q151, L152, V153, R154, E156, P157, N158, V159, S160, Y161, I162, C163, 
S164, R165, Y166  
• ATP binding site (Figure 2.18: yellow): I7, G8, N9, G10, V15, A28, K30, V55, L77, 
E78, Y79, V80, T83, K128, Q130, N131, L133, D145  
• Polypeptide substrate binding site (Figure 2.18: red): R41, Y85, D126, K128, S148, 
V159, Y161, I162, C163, S164, Y166, G204  
• Axin site (Figure 2.18: orange): I173, V208, D209, L211, V212, I215, K216, F236, 
K237, F238, P239, Q240, I241  
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• Active site (Figure 2.18: blue): I7, G8, N9, G10, S11, V15, A28, K30, R41, V55, L77, 
E78, Y79, V80, T83, Y85, R86, D126, K128, Q130, N131, L133, D145, S148, V159, 
Y161, I162, C163, S164, Y166, G204  
• Dimer interface (Figure 2.18: wheat): S11, F12, P157, N158, V159, S160, Y161, I162, 
C163, S164, R165, I173, F174, D205, S206, G207, V208, D209, L211, V212, K216, 
F236, K237, F238, P239 
 
Figure 2.17. GSK-3α motifs: Activation loop is shown in green, ATP binding site in yellow, 
polypeptide binding site in red, axin site in orange, active site in blue and dimer interface in 
wheat. The protein is shown as white cartoon except for the described motifs. 
 
 
 
 
 
77 
2.3. Construction of 3D model of PKC-ε 
 PKC-ε is a serine/threonine-protein kinase which is calcium-independent and 
phospholipid-dependent271. PKC-ε was found to have essential roles in the regulation of several 
cellular processes including multiple functions associated with cytoskeletal proteins (cell cycle, 
cell adhesion, motility and migration). PKC-ε play important functions in ion channel regulation 
and neuron growth, which is found to be important in AD271.  
 
2.3.1. Homology modeling method  
 The amino acid sequence of human PKC-ε was downloaded from the UniProt database. 
We used the typical homology modeling procedure to construct the 3D models similar to what 
we did in case of CDK1 model. We validated the homology models using the protein quality 
option of Bioluminate and by Procheck software. 3DLigandSite and protein family features were 
used to predict ligand binding pockets and structural motifs.  
 
2.3.2. Results and discussion 
 PKC-ε contains 737 amino acids and is found in one isoform. The following is the 
amino acid sequence of PKC-ε as downloaded from the Uniprot database. We highlighted in 
green the amino acids residues from 169 to 220, which represent the first zinc finger domain 
(C1A, Phorbol-ester/DAG-type 1). The residues from 242 to 292 represent the second zinc finger 
domain (C1B, Phorbol-ester/DAG-type 2) and are highlighted in cyan. The residues from 408 to 
668 characterize the kinase domain and are highlighted in yellow.			
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        10         20         30         40         50 
MVVFNGLLKI KICEAVSLKP TAWSLRHAVG PRPQTFLLDP YIALNVDDSR  
        60         70         80         90        100 
IGQTATKQKT NSPAWHDEFV TDVCNGRKIE LAVFHDAPIG YDDFVANCTI  
       110        120        130        140        150 
QFEELLQNGS RHFEDWIDLE PEGRVYVIID LSGSSGEAPK DNEERVFRER  
       160        170        180        190        200 
MRPRKRQGAV RRRVHQVNGH KFMATYLRQP TYCSHCRDFI WGVIGKQGYQ  
       210        220        230        240        250 
CQVCTCVVHK RCHELIITKC AGLKKQETPD QVGSQRFSVN MPHKFGIHNY  
       260        270        280        290        300 
KVPTFCDHCG SLLWGLLRQG LQCKVCKMNV HRRCETNVAP NCGVDARGIA  
       310        320        330        340        350 
KVLADLGVTP DKITNSGQRR KKLIAGAESP QPASGSSPSE EDRSKSAPTS  
       360        370        380        390        400 
PCDQEIKELE NNIRKALSFD NRGEEHRAAS SPDGQLMSPG ENGEVRQGQA  
       410        420        430        440        450 
KRLGLDEFNF IKVLGKGSFG KVMLAELKGK DEVYAVKVLK KDVILQDDDV  
       460        470        480        490        500 
DCTMTEKRIL ALARKHPYLT QLYCCFQTKD RLFFVMEYVN GGDLMFQIQR  
       510        520        530        540        550 
SRKFDEPRSR FYAAEVTSAL MFLHQHGVIY RDLKLDNILL DAEGHCKLAD  
       560        570        580        590        600 
FGMCKEGILN GVTTTTFCGT PDYIAPEILQ ELEYGPSVDW WALGVLMYEM  
       610        620        630        640        650 
MAGQPPFEAD NEDDLFESIL HDDVLYPVWL SKEAVSILKA FMTKNPHKRL  
       660        670        680        690        700 
GCVASQNGED AIKQHPFFKE IDWVLLEQKK IKPPFKPRIK TKRDVNNFDQ  
       710         720          730 
 DFTREEPVLT LVDEAIVKQI NQEEFKGFSY FGEDLMP 	
In this case, we are interested in modeling the zinc finger domain type 2 (C1B) because 
of the studies have confirmed its role in AD if activated. We decided to model both the kinase 
and C1B domains to ensure a complete picture of the enzyme. We used the specific protein 
family information to select the amino acid sequence for modeling. In case of the kinase domain 
the E-value was 3.8e-68. We selected protein kinase C, alpha type (PDB ID: 3IW4, Figure 2.18) 
as a template to model the target sequence because they share more than 65% homology identity. 
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We then constructed 10 models, and the variable loop was found to be far from the expected 
ligand binding area (Figure 2.19).   
The model was validated using Bioluminate and Procheck softwares. All amino acids 
were found in the permitted regions of the Ramachandran plot (Figure 2.20), 95.4% of the amino 
acids are in the main regions and 4.6% in the generously allowed ones. Chi1-chi2 angles, the 
main and the side chain parameters are analogous to well-refined structures at resolution of 2.5 
Å. Residue properties show a maximum aberration of 2.1 Å with no bad contacts.  
We applied the Protein Patch Analyzer to search for the hydrophobic and hydrophilic 
possessions of the models (Figure 2.21). This was done employing the van der Waals solvent 
accessible interaction surface calculations. The surface of negative and positive potential was 
calculated using oxygen atom probe. The patch analyzer did not show any surface exposed 
tryptophan residues. There is no exposed tyrosine residues or other residues with exposed 
oxygen atoms.  
The expected ligand binding pockets and the amino acid residues surrounding them were 
detected by 3DLigandSite. To do so, we used the information from the structurally similar 
proteins. The protein structures were aligned using the 3D model as the reference of frame to 
place the ligands and predict the ligand binding pockets (Figures 2.22 and 2.23). A 26 protein 
structures (Table 2.8) were found to have similar binding sites, and the coordinates of their 
ligands were transmitted to the 3D model. The positions of Mg2+ in the binding site were 
calculated (Figure 2.24 and Table 2.9). 
 
 
 
 
80 
 
Figure 2.18. Sequence alignment and secondary structure assignment of the query (-new-0) and 
template structures. The globally conserved amino acid residues (new-0-pfam), and the template 
protein (3IW4272, human PKC-α) are colored based on matching. SSPro was used to assign the 
secondary structures. 
 
 
Figure 2.19. Cartoon representation of the kinase domain of PKC-ε models colored yellow for 
α-helices, red for β-sheets and green for loops. The loops that are modeled to be flexible are 
shown in boxes, and are found to be far from the ligand binding sites (indicated by cyan arrow). 
Kinase domain of PKC-ε is bilobial with the N lobe consists mostly of β-sheets and the C lobe 
consists mostly of α-helices. The binding pocket is at the intersection of the two lobes. 
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                                    Figure 2.20. Ramachandran plot of PKC-ε model. 
 
 
Figure 2.21. The aggregation-prone regions (APRs) in the PKC-ε model. The kinase domain of 
PKC-ε is shown as cartoon. The β-sheets are colored yellow and α-helices are colored red. The 
hydrophobic patches are colored green, the negative patches are colored red and the positive 
patches are colored blue. 
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Figure 2.22. `similar protein structures (PDB codes: 3C50273, 3C4Z273, 3C4W273, 3C51273, 
3C4X273, 2ACX274, 1RDQ275, 1Q24276, 1L3R277, 2V55278, 1MQ4279, 1OL5280, 1JKK281) aligned 
with the kinase domain model of PKC-ε. The protein structures are shown as cartoon with 
distinct color for each protein. 
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Figure 2.23. A cartoon representation of the PKC-ε model showing the ligand binding sites. All 
ligands are extracted from other known experimentally defined proteins. Ligands are shown as 
sticks and metal ions as green spheres. The amino acid residues surrounding the ligand binding 
pockets are shown as blue spots and the other parts of the protein are shown as grey cartoon. 
 
Table 2.9. The ligands and PDB files used to predict the active site of PKC-ε model. 
Ligand Count Source structures 
STU 2 1STC, 1OKY 
MG 18 3C50, 3C4Z, 3C4W, 3C51, 3C4X, 2ACX, 1RDQ, 1Q24, 1L3R, 
2V55, 1MQ4, 1OL5, 1JKK 
ADP 9 3C50, 3C4Z, 3C51, 2QUR, 1RDQ, 1JBP, 1L3R, 1MQ4, 1OL5 
ATP 10 2BIY, 3HRF, 3HRC, 3C4W 3C4X 1H1W, 3FJQ, 1RDQ, 1Q24, 
1ATP 
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Figure 2.24. Predicted active site of the kinase domain of PKC-ε model. Amino acid residues 
surrounding the binding pocket are shown as grey sticks, and the possible positions of Mg2+ ions 
based on binding site similarity with known protein structures are shown as green spheres. 
 
Table 2.10. The amino acid residues included in the active site of PKC-ε.  
Residue Amino acid Contacts Average distance 
7 LEU 14 0.34 
8 GLY 21 0.19 
9 LYS 22 0.00 
10 GLY 22 0.03 
11 SER 28 0.02 
12 PHE 19 0.02 
13 GLY 19 0.17 
15 VAL 21 0.00 
28 ALA 21 0.08 
30 LYS 20 0.00 
63 THR 13 0.42 
79 MET 11 0.57 
80 GLU 21 0.05 
81 TYR 10 0.48 
82 VAL 21 0.19 
129 ASP 12 0.27 
130 ASN 15 0.41 
132 LEU 21 0.27 
143 ASP 27 0.11 
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Other sites and domains include: 
• Activation loop (Figure 28, red spots):  A142, D143, F144, G145, M146, C147, K148, 
E149, G150, I151, L152, N153, G154, V155, T156, T157, T158, T159, F160, C161, 
G162, T163, P164, D165  
• ATP binding site (Figure 25, orange spots): L7, G8, K9, G10, S11, V15, A28, K30, 
T63, E80, Y81, V82, D86, D125, K127, D129, N130, L132, A142, D143  
• Polypeptide substrate binding site (Figure 25, orange spots):  S11, D86, M88, D125, 
K127, D129, M148, F160, C161, G162, T163, P164, D165, E192, P198, E201  
 
 
Figure 2.25. PKC-ε structural motifs: its activation loop is shown in red, with its ATP binding 
site in orange and polypeptide binding site in green. The protein is shown as white cartoon 
except for the designated motifs. 
 
In case of the C1B domain the E-value was 1.2-16 for Phorbol-ester/DAG-type 2. We used 
the first solved structure of human PKC C1 domain, theta type (PDB ID: 2ENZ282, Figure 2.26) 
as a template to model the target sequence because they share more than 67% homology identity. 
We then constructed 20 models because the percentage of the disordered structure was about 
22% (Figure 2.27).  The models were validated using Bioluminate and Procheck softwares. All 
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amino acids were found in the acceptable sections of the Ramachandran plot (Figure 2.28), 98% 
of the amino acids are in the core areas and 2% in the generously allowed ones. Chi1-chi2 
angles, the main and the side chain parameters are similar to well-refined structures at resolution 
of 2.5 Å. Residue properties demonstrated a maximum deviation of 1.2 Å with no bad contacts. 
We utilized the Protein Patch Analyzer to find the hydrophobic and hydrophilic properties of the 
models (Figure 2.29).  
The expected ligand binding pockets and the amino acid residues surrounding them were 
detected by 3DLigandSite and fpocket283, 284 (geometry-based cavity detection algorithm). We 
used the knowledge from the structurally related proteins. The protein structures were aligned 
using the 3D model as the reference of structure to place the ligands and predict the ligand 
binding pockets (Figure 2.30). Nineteen structures (Table 2.10) were found to have similar 
binding sites, and the coordinates of their ligands were transmitted to the 3D model. The 
positions of ZN2+ in the binding site were calculated (Figure 2.30 and Table 2.11). We checked 
the orientation of proteins in membranes (OPM) database285, 286 to find out how could C1B 
domain attaches to the plasma membrane.  
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Figure 2.26. Alignment of PKC-ε C1B domain (query) and the second c1 domain from human2 
protein kinase c theta (PDB ID: 2ENZ as template) sequences, showing 1: predicted secondary 
structures; 2: query sequence; 3: template sequence; 4: template known secondary structure, 5: 
template predicted secondary structure. Brown blocks are for insertions relative to the template. 
Orange blocks are for deletions relative to the template. Secondary structure information is 
represented using: T for hydrogen bonded turn; B for residue in isolated β-bridge; and S for 
bend. Identical residues are highlighted with a grey background.  
 
 
Figure 2.27. Cartoon representation of the aligned C1B domain models colored yellow for the 
α-helices, red for the β-sheets and green for loops. The amino acid residues are shown as lines 
with unique color for each model. 
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Figure 2.28. The Ramachandran plot of the C1B domain of PKC-ε model. 
 
Figure 2.29. The aggregation-prone regions (APRs) in the C1B domain of PKC-ε. The C1B 
domain is shown as cartoon colored yellow for the β-sheets and red for the α-helices. The 
hydrophobic patches are colored as green surface, negative patches are colored in red and 
positive patches are colored in blue. 
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Figure 2.30. A cartoon representation of the C1B domain model of PKC-ε showing the Zinc 
binding site. Zinc ions as violet spheres. The protein is shown as grey cartoon. The expected 
membrane orientation is shown, with the upper cell membrane shown as red spheres and the 
lower as blue sphere. 
 
Table 2.11. The ligand and PDB files used to predict the Zinc binding site. 
Heterogen Count Source structures 
ZN 258 3CXL, 3BJI, 2YUU, 2ENZ, 2ENN, 
2ELI, 2E73, 2DB6, 1Y8F, 1XA6, 
1R79, 1PTR, 1PTQ, 2VRW, 1TBO, 
1TBN, 2ROW, 1X4J, 1RFH 
 
Other sites and domains include: 
• Zinc binding sites (Figure 31, green spots): H2, C15, C18, C32, C35, H40, C43, C51 
• Putative DAG/PE binding site (Figure 31, red spots): Y9, P12, T13, L22, W23, G24, 
L25, L26, R27, Q28  
• Putative RAS interaction site (Figure 2.31, yellow spots): P12, F14 
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Figure 2.31. PKC-ε C1B motifs: Zinc binding sites are shown in green, putative DAG/PE 
binding site in red, putative RAS interaction site in yellow. The protein is shown as white 
cartoon except for the described motifs. 
 
2.4. Summary 
 For the protein kinases, whose experimental structures have not been solved yet, we 
followed the standard procedures of comparative modeling to construct their expected 3D 
models. We used Prime module of the Schrödinger suite to create and refine the 3D models. We 
used Bioluminate and Procheck softwares for the assessment of the models. All amino acids 
were found to be in the allowed or the generously allowed regions of the Ramachandran plot. 
Chi1-chi2 angles, the main and the side chain parameters were comparable to well-refined 
structures at a resolution of 2.5 Å. Residue properties showed a maximum deviation of 2.1 Å 
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with no bad contacts. We applied the Protein Patch Analyzer to check for the hydrophobic and 
hydrophilic properties of the generated models.  In addition, we used knowledge from 
structurally similar proteins to define the amino acid residues in the ATP binding site as well as 
in other important sites and motifs. 
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                                       Manal A. Nael and Robert J. Doerksen 
CHAPTER 3. STRUCTURAL ANALYSIS AND THERMODYNAMIC CALCULATIONS OF 
THE ACTIVE SITES OF CDK1, CDK5, GSK-3 AND PERK 
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3.1. Introduction 
We performed structural analysis of the protein kinases involved in AD. We studied the 
different motifs’ structures such as ATP binding site, ligand binding pocket, and activation loop. 
We also identified the conserved structural water molecules of CDK5, GSK3β and PERK (have 
many experimentally solved kinase domains). In addition, we performed thermodynamic and 
water mapping calculations for the active sites to estimate the effects of ligand’s functional 
groups modifications on its binding affinity. 
 
3.2. Methods 
3.2.1. Searching for conserved motifs 
We explored for the common structural motifs and domains of GSK-3β, CDK5 and 
PERK using the Conserved Domain Database287 by applying PSI-BLAST variant227, RPS-
BLAST287, to scan against pre-calculated position-specific scoring matrices (PSSMs)288. To 
ensure high confidence associations between the query sequence and conserved domains, an 
expectation value of 0.01 was used.  
 
3.2.2. Identifying experimentally conserved water molecules 
To identify the consensus water molecules in GSK-3β, CDK5 and PERK, we retrieved all 
the X-ray crystal structures with high resolution (≤ 3.0 Å), which are similar to the query 
structures. The structures are then split into their individual chains and superimposed with the 
query structure. We selected the PDB files (4AU8289 for CDK5, 1QI4290 for GSK-3β and 
4G31213 for PERK) as the search inquiries. Only structures of at least 95% sequence identity with 
the query structures were considered. Mobility is used for quality refinement of water in all 
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crystal structures291. Mobility is defined by the crystallographic temperature factor (B-factor) and 
the atom occupancy. Water molecules are discarded if their oxygen atoms showed mobility 
values >2.0 Å for each structure. Crystal structures after refinement were aligned to the query 
structures using the backbone as the reference291. Then, hierarchical clustering was performed on 
the 3D Cartesian coordinates of all the water molecules. Euclidean distance metric, the complete 
linkage algorithm, was used in clustering to ensure that at most, only one water molecule from 
each superimposed structure is present in the cluster291. Then, the degree of water conservation 
was calculated as the number of water molecules in a cluster divided by the total number of 
aligned protein structures. Clusters having a degree of conservation of 0.47 were considered as 
conserved. 
  
3.2.3. Water mapping 
We used SZMAP292 to analyze the thermodynamic properties of the ligand-binding 
pocket of CDK1, CDK5, GSK-3α, GSK-3β and PERK. Water mapping calculations are useful in 
identifying the essential and artificial active site’s water molecules. As well these calculations 
help in suggesting ligand substitutions. Proper protein and ligand preparations are required 
before starting SZMAP calculation. FIXDUPATOMNAMES292 was used to standardize atom 
types & names and to remove duplicated atom names. REDUCE293 and PrepWizard294, 295 were 
used to explicitly add hydrogen atoms to the protein–ligand complex. MKHETDICT292 was used 
to generate the PDB heterogen dictionary that is required by REDUCE to allow for proper ligand 
protonation. All OH and SH groups of all amino acids, and the CH3 of methionine were allowed 
to rotate. The structures were then split into protein and ions in one file and ligand in another file 
using PCH292. AmberFF94296 forcefield and charges were used to assign the partial charges for 
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amino acids and AM1BCC297 was used for the small organic compounds. We calculated the 
regions of solvent stabilization and destabilization of the protein-ligand complex, apoprotein and 
the ligand, were calculated using an explicit water molecules probe. The excess free energy was 
determined for the water molecules and in particular those that can be displaced by the ligand298.  
In general, SZMAP algorithm292 for studying the thermodynamic properties of the active site is 
based on a semi-continuum solvent approach in which water molecules will be desolvated by the 
effect of the solute (ligand molecule) and each of such water molecules is supposed to have 
many possible orientations. The ones with their protons closer to the solute are believed to be 
more solvated. By sampling enough orientations, the partition function can be calculated as 
(Equation 1): 
  (1) 
where Q is the partition function, Ej is the energy value for each probe water orientation j.  Ej is 
given as (Equation 2): 
  (2) 
Ej is the sum of the Poisson-Boltzmann (PB) protein:water Coulombic interaction energy 
[PBint(P:W)], protein desolvation (P*desolv, for speed purposes, it is computed once per grid point 
using a spherical united-atom representation of the probe water), water desolvation (Wdesolv) 
penalties and the van der Waals energy (VDW[j=1…Norient]). FRED shape scoring function is 
used to provide positions of water that would make contact with protein and remove points that 
VDW would disallow. For each water orientation, a potential field is calculated throughout the 
protein. The rotationally averaged free energy of each water orientation is calculated. The 
probability292 (prob) of each water orientation (j) is given by Equation 3: 
Q = e−
Ej
kT
j=1
Norient
∑
Ej = PBint (P :W )+Pdesolv* +Wdesolv +VDW[ j =1...Norient ]
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(3) 
The entropic and enthalpic contributions are calculated, the probe water orientation 
entropy (Equation 4), free energy (Equation 5) and enthalpy (Equation 6) differences from 
continuum water are calculated by: 
 (4) 
 (5) 
(6) 
GAMEPLAN292 was then used to provide suggestions for ligand substitutions to improve 
its binding affinity to the protein target. This lead optimization plans would be of value to 
increase the hit rate to identify more active hits. 
 
3.3. Results and discussion 
3.3.1. Structural analysis 
The kinase domain is conserved and protein alignment of the crystal structures of PERK 
(PDB code: 4G31213), CDK5 (PDB code: 1UNL143), GSK-3β (PDB code: 1Q41167) and 3D 
models of CDK1, and GSK-3α showed similar ligand binding pockets (Figure 3.1). The structure 
of kinases shows several conserved structural motifs and domains that contribute to their 
function and ligand binding. The kinase domain is made up of about 300 residues organized in 
two domains (N- and C-lobes) as eight α-helices (αB-αI) and nine strands (β1-β9) (Figure 3.2). 
The N-terminal (N-lobe) domain is composed of about 80 amino acids and formed of five anti-
parallel β-sheets and two α-helices (β1-β2-β3-αB-αC-β4-β5)299. The C-terminal (C-lobe) domain 
probj =
e−
E
kT
Q
TΔS = (−kT probj ln probj )− kT lnNorientj=1
Norient∑
ΔG = −(kT lnQ− kT lnNorient )
ΔH = ΔG +TΔS
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has about 200 amino acids residues and contains six major α-helices (αD-αI) and four β-sheets 
(β6-β9).  
Kinases contain some conserved structural domains and motifs including G-loop, αC-
helix, hinge region, HRD domain, activation loop and DFG region. Glycine rich loop (G-loop, P-
loop or Walker A motif) is highly flexible loop and is located between β1 and β2 strands in the 
N-lobe. G-loop consists of about 10 amino acid residues with the general sequence of 
HGXGX(Y/F)GXVH motif, where H for any hydrophobic amino acid residue such as Gly, Ala, 
Val, Leu, Ile, Pro, Phe, Met, and Trp. G for glycine, X for any amino acid, Y for tyrosine, F for 
phenylalanine and V for valine residues299.  
In CDK5, G-loop consists of ILe10, Gly11, Glu12, Gly13, Thr14, Tyr15, Gly16, Thr17 
and Val18 (Figure 3.3). The G-loop of GSK-3β contains Ile62, Gly63, Asn64, Gly65, Ser66, 
Phe67, Gly68, Val69 and Val70 (Figure 3.4). PERK has a G-loop consisting of Leu598, Gly599, 
Arg600, Gly601, Gly602, Phe603, Gly604, Val605 and Val606 (Figure 3.5). 
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Figure 3.1. Structure alignment of CDK1 (3D model, blue), CDK5 (PDB code 1UNL, red), 
GSK-3α (3D model, yellow), GSK-3β (PDB code: 1Q41, green) and PERK (PDB code: 4G31, 
pink). 
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Figure 3.2. Cartoon representation of the structural elements of protein kinases using CDK5 as 
an example (PDB code: 1UNL), showing the N- and C-lobes. 
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Figure 3.3. The G-loop of CDK5. The amino acid residues representing the G-loop are shown as 
sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green loops. 
 
Figure 3.4. The G-loop of GSK-3β. The amino acid residues representing the G-loop are shown 
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green 
loops. 
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Figure 3.5. The G-loop of PERK. The amino acid residues representing the G-loop are shown as 
sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green loops. 
 
The conserved lysine residue300 is positioned at the end of β3 strand of the N-lobe and 
forms salt-bridge with the conserved glutamate, which is placed at the middle of αC-helix. The 
distance between Lys33 and Glu51 is about 3.0 Å in CDK5 (Figure 3.6) which similar to that of 
GSK-3β (Lys85…Glu97) (Figure 3.7). However, the distance between Lys662 and Glu639 is 7.5 
Å in PERK (Figure 3.8). 
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Figure 3.6. Conserved lysine of CDK5. The amino acid residues representing the conserved Lys 
are shown as sticks. The slat-bridge between Lys and Glu is shown as a yellow line. The protein 
is represented as cartoon with yellow α-helices, red β-sheets and green loops. 
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Figure 3.7. Conserved lysine of GSK-3β. The amino acid residues representing the conserved 
Lys are shown as sticks. The slat-bridge between Lys and Glu is shown as yellow line. The 
protein is represented as cartoon with yellow α-helices, red β-sheets and green loops. 
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Figure 3.8. Conserved lysine of PERK. The amino acid residues representing the conserved Lys 
are shown as sticks. The slat-bridge between Lys and Glu is shown as yellow line. The protein is 
represented as cartoon with yellow α-helices, red β-sheets and green loops. 
 
The activation loop (A-loop or T-loop) of kinases is the amino acid residues that are the 
two conserved motifs DFG and APE301. A-loop has the DFG-loop at its N-terminal part 
preceding the phosphorylation site amino acid residue, which could be serine, threonine, or 
tyrosine, and at the C-terminal region there is the APE motif. The activation segment of CDK5 
begins with the conserved DFG motif (NFG in CDK5) till the APE domain, which is mutated to 
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PPD in this kinase. The segment contains Mg2+ binding regions (DFG), the β9 strand, the 
phosphorylation site, and the P+1 loop. CDK5 has an A-loop consisting of the following residues 
Ala143, Asn144, Phe145, Gly146, Leu147, Ala148, Arg149, Ala150, Phe151, Gly152, Ile153, 
Phe154, Val155, Arg156, Cys157, Tyr158, Ser159, Ala160, Glu161, Val162, Val163, Thr164, 
Leu165, Trp167, Tyr168, Arg169, Pro170, Pro171 and Asp172 (Figure 3.9). 
 
Figure 3.9. The A-loop of CDK5. The amino acids residues representing the A-loop are shown 
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green 
loops. 
 
The A-loop of GSK-3β consists of the following amino acid residues; Asp200, Phe201, 
Gly202, Ser203, Ala204, Lys205, Gln206, Leu207, Val208, Arg209, Gly210, Glu211, Pro212, 
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Asn213, Val214, Ser215, Tyr216, Ile217, Cys218, Ser219, Arg220, Tyr221, Tyr222, Arg223, 
Ala224, Pro225 and Glu226 (Figure 3.10). The A-loop PERK contains Asp954, Phe955, Gly956, 
Leu957, Val958, Thr959, Ala960, Met961, Asp962, Gln963, Asp964, Glu965, Glu966, Glu967, 
Gln968, Thr969, Val970, Leu971, Thr972, Pro973, Met974, Pro975, Ala976, Tyr977, Ala978, 
Arg979, His980, Thr981, Gly982, Gln983, Val984, Gly985, Thr986, Lys987, Leu988, Tyr989, 
Met990, Ser991, Pro992 and Glu993. In the experimental X-ray crystal structures of PERK, the 
amino acids highlighted in yellow above are missing. 
 
Figure 3.10. The A-loop of GSK-3β. The amino acid residues representing the A-loop are shown 
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green 
loops. 	 	DFG regions302 (Figures 3.11-3.13) affect kinase conformation and hence the type of 
enzyme inhibitor. Based on the published reports, the inactive kinase conformation (DFG-out) is 
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because of a Phe turn of ~120°. Phosphorylation of Thr/Ser, or Tyr amino acids leads to kinase 
activation to adopt DFG-in conformation and the A-loop will be moved away from the active site 
aiding in substrate binding. The flipping of DFG in the inactive state leads to a 45° rotational 
motion of the αC-helix disrupting the salt bridge between the conserved Lys and Glu (Figure 3.6-
3.8). 
 
Figure 3.11. DFG-loop of CDK5. The amino acid residues representing the DFG-loop are shown 
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green 
loops. 
 
 
108 
 
Figure 3.12. DFG-loop of GSK-3β. The amino acid residues representing the DFG-loop are 
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
	
Figure 3.13. DFG-loop of PERK. The amino acid residues representing the DFG-loop are shown 
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green 
loops. 
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Kinase domain is bilobar with a small N-lobe and a large C-lobe. The N-lobe contains the 
nucleotide binding site and the C-lobe contains the substrate recognition site. The ATP and ATP 
analogues bind to the deep cleft between the N- and C-lobes302. Most kinase inhibitors (Figures 
3.14-3.16) bind to this cleft mostly aided by hydrophobic and hydrogen bonding types of 
interactions. 
 
 
Figure 3.14. The ligand binding pocket of CDK5, showing key amino acid residues involved in 
the interaction ligands. The protein is represented as cartoon with yellow α-helices, red β-sheets 
and green loops. 
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Figure 3.15. The ligand binding pocket of GSK-3β, showing key amino acid residues involved 
in the interaction ligands. The protein is represented as cartoon with yellow α-helices, red β-
sheets and green loops. 
 
	
Figure 3.16. The ligand binding pocket of PERK, showing key amino acid residues involved in 
the interaction ligands. The protein is represented as cartoon with yellow α-helices, red β-sheets 
and green loops. 
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The kinase binding pocket303 is usually divided into a set of sub-pockets, named: adenine 
(AP), ribose (RP), phosphate (PP), solvent (SP), back (HPI) and hydrophobic allosteric (HPII). 
The sub-pocket of adenine is generally hydrophobic in nature and composed of the hinge region 
and gatekeeper residue (GK). The amino acid residues of β1, β2, β3, αC, β4, and β7 surround the 
AP and contribute to the hydrophobicity.  The size of the GK residue regulates the size of the AP 
derivative, and thus plays a role in kinase specificity. In CDK5 the GK is Phe80 that is larger 
than those of GSK-3β (Leu132) and PERK (Met888) (Figures 3.17-3.19). 
 
 
Figure 3.17. The GK of CDK5. The amino acid residues representing the GK−1 to GK+3 are 
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
 
 
112 
	
Figure 3.18. The GK residue of GSK-3β. The amino acid residues representing the GK−1 to 
GK+3 are shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-
sheets and green loops. 
	
 Figure 3.19. The GK of PERK. The amino acid residues representing the GK−1 to GK+3 are 
shown as sticks. The GK residue is shown in two orientations. The protein is represented as 
cartoon with yellow α-helices, red β-sheets and green loops. 
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The hinge region (Figures 3.20-3.22) is the linker between β5 strand and αD helix and 
contains amino acid residues starting from GK+1 to GK+3 in relation to the location of the GK 
residue303. The adenine of ATP forms hydrogen bonds with the hinge region. Till date, most of 
the discovered kinase inhibitors are found to form one to three hydrogen bonds with the amino 
acids residing in the hinge region mimicking the hydrogen bonds formed by the adenine group.  
 
Figure 3.20. The hinge region of CDK5. The amino acid residues representing the hinge region 
are shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
 
 
114 
	
Figure 3.21. The hinge region of GSK-3β. The amino acid residues representing the hinge 
region are shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-
sheets and green loops. 
	
Figure 3.22. The hinge region of PERK. The amino acid residues representing the hinge region 
are shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
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The Phe amino acid residue of the DFG motif shows hydrophobic interactions with the 
αC-helix and His–Arg–Asp (HRD) motif303 (Figures 3.23-3.25).  This motif is highly conserved 
in protein kinases. Based on the degree of conservation Asp member is the most conserved 
amino acid amongst the three.  The HRD aspartate aids in orienting the P-site group of the 
peptide substrate. The Arg residue of the HRD motif is found only in the eukaryotic kinases. The 
HRD Arg supports the geometry of the A-loop for the required phosphorylation.  
 
Figure 3.23. The HRD motif of CDK5. The amino acid residues representing the HRD are 
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
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Figure 3.24. The HRD motif of GSK-3β. The amino acid residues representing the HRD are 
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
	
Figure 3.25. The HRD motif of PERK. The amino acid residues representing the HRD are 
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
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CDK5 varies from other CDK family members in many aspects including its activation 
by p35 and p39 rather than cyclins. The interface between p35/p25 and the active CDK5 is close 
to other CDK family members, suggesting similar activation mechanism143. Hyperactivation of 
CDK5 when it binds with p25 leads to hyperphosphorylation of tau in AD. Exposure to Aβ 
peptides leads to truncation of p35 to p25 that is a CDK5 activator. p25 protein binds selectively 
with CDK5 (Figures 3.26-3.28) and does not bind or activate any other member of the CDK 
family143.  
 
 
Figure 3.26. The interface of CDK5-p25. The Cα of the residues at the interface are shown as 
spheres. The amino acid residues of CDK5 at the interface are colored orange, and that of p25 as 
pink. The protein is represented as cartoon with yellow α-helices, red β-sheets and green loops. 
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Figure 3.27. The interface of CDK5-p25. The amino acid residues of CDK5 at the interface are 
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
	
Figure 3.28. The interface of CDK5-p25. The amino acid residues of p25 at the interface are 
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and 
green loops. 
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The six sub-pockets of the kinase active site are previously mentioned as adenine (AP), 
ribose (RP), phosphate (PP), solvent (SP), back (HPI) and hydrophobic allosteric (HPII). The 
sub-pocket HPI is hydrophobic in nature. The GK residue controls the entry of the inhibitor to 
the HPI sub-pocket. The hydrophilic sub-pocket (RP) is adjacent to the hydrophobic sub-pocket 
AP, the solvent exposed pocket (SP), and G-loop (Figure 3.27). The PP sub-pocket is close to 
Asp of the DFG-loop. The hydrophilic sub-pocket SP is adjacent to the terminal end of hinge 
region. The hydrophobic allosteric sub-pocket (HPII) is not conserved and can be targeted for 
kinase specificity. We analyzed the protein-ligand interactions for CDK5, GSK-3β and PERK 
(Figures 3.29-3.32, and Tables 3.1-3.1) using one crystal structure for each as an example. 
 
 
Figure 3.29. The six sub-pockets of the kinase 
binding site using CDK5 (PDB code 4AU8289) 
for illustration, adenine (AP), ribose (RP), 
phosphate (PP), solvent (SP), back (HPI) and 
hydrophobic allosteric (HPII). The amino acids 
participating in ligand interactions are shown as 
sticks Tyr15 (G-loop), Asp144-Gly146 (DFG), 
Phe80 (GK), Glu81-Asp84 (Hinge), Lys33 
(Conserved Lys), and Glu51 (αC-helix). 
HPII
PP
RP
SP
AP
HPI
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Figure 3.30. The CDK5-ligand interaction (PDB code: 4AU8289). 
Table 3.1. Ligand Interactions Report (PDB code: 4AU8289). 
Ligand Receptor Interaction Distance E (kcal/mol) 
N7 O HOH2089(A) H-donor 2.78 -3.1 
S13 O Cys83(A) H-donor 3.06 -0.3 
C14  O HOH2089(A) H-donor 3.43 -1.1 
N18  O Ile10(A) H-donor 2.76 -5.9 
N18  OD2 Asp86(A) H-donor 2.91 -3.8 
N18  O HOH2101(A) H-donor 3.56 -1.1 
N18 O HOH2102(A) H-donor 3.85 -1.2 
O16  O HOH2095(A) H-acceptor 3.57 -0.7 
O16  O HOH2254(A) H-acceptor 3.25 -1.5 
O17  CA Gln85(A) H-acceptor 3.43 -0.8 
O17   N Asp86(A) H-acceptor 3.03 -2.1 
N18  O HOH2101(A) H-acceptor 3.56 -0.7 
5-ring CG1 Val18(A) pi-H 3.92 -0.6 
 
 
121 
 
 
Figure 3.31. GSK-3β-ligand interaction (PDB code: 4AFJ304). 
 
Table 3.2. Ligand Interactions Report (PDB code: 4AFJ304).  
Ligand Receptor Interaction Distance E (kcal/mol) 
C11 O Asp133(A) H-donor 3.04 -1.9 
N16 O Val135(A) H-donor 2.65 -0.9 
N12 N Val 135(A) H-acceptor 3.36 -1.6 
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Figure 3.32. PERK-ligand interaction (PDB code: 4G31213). 
 
Table 3.3. Ligand Interactions Report (PDB code: 4G31213).  
Ligand Receptor Interaction Distance E(kcal/mol) 
N03  O GLN888(A) H-donor  2.82 -2.6 
N3  O HOH1355(A) H-acceptor 2.87 -2.3 
O4  O HOH1356(A) H-acceptor 3.02 -2.6 
N04  N CYS890(A) H-acceptor  2.79 -4.5 
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3.3.2. Active site hydration 
Protein-ligand complex is usually stabilized by solvation and desolvation of the active 
site. In the apoprotein water molecules are in ordered state and upon ligand binding some of the 
waters displaced to accommodate the ligand. Some of the water molecules are buried and 
required to maintain the protein geometry. These water molecules are conserved. Water 
molecules in the active site form hydrogen bonds with or are displaced by the ligand. To define 
the conserved water molecules in the studied kinases, we averaged all water molecules from the 
experimentally solved crystal structures. Water molecules that showed mobility of less than 2.0 
Å are clustered and the degree of conservation is then calculated.  
In case of CDK5, six PDB structures [PDB codes: 1H4L305, 1UNG142, 1UNH142, 
1UNL142, 2O0G306, 4AU8289, Figure (3.33)] are used in this calculation because they have 
resolution of ≤ 3.0 Å. All kinase chains are extracted and considered in this study (i.e. we used 
12 kinase chains). We found 32 water molecules with conservation degrees of 0.66 to 1.00 
(Figures 3.34). Three water molecules are found in the active site forming hydrogen bonding 
network with Thr14, Lys33, Glu51, His124, Ala143, Asp144, Phe145 and Gly146 (Figures 3.35-
3.36). These conserved waters are believed to play important roles in ligand binding and will be 
necessary to consider them in docking experiments and virtual screening calculations.  
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Figure 3.33. Superimposed CDK5 structures showing the conserved water molecules.  
 
Figure 3.34. CDK5 conserved water molecules. Waters are colored based on the degree of 
conservation from red to blue. Degree of water conservation ranges from 0.667 to 1.00 
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Figure 3.35. CDK5 conserved water molecules. There are three conserved active site waters 
having several hydrogen bonds with the surrounding amino acids. 
 
Figure 3.36. CDK5 conserved water molecules. The active site waters in the aligned structures. 
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In case of GSK-3β, we retrieved 44 PDB structures from the protein databank repository 
(PDB codes: 1GNG307, 1H8F308, 1I09308, 1J1B245, 1J1C245, 1O9U309, 1PYX167, 1Q3D167, 
1Q3W167, 1Q41167, 1Q4L167, 1Q5K168, 1R0E169, 1UV5310, 2JLD170, 2OW3311, 3DU8172, 3F7Z312, 
3F88312, 3GB2173, 3I4B174, 3L1S175, 3PUP313, 3Q3B176, 3SAY314, 3SD0177, 3ZDI178, 3ZRK179, 
3ZRL179, 3ZRM179, 4ACC180, 4ACD180, 4ACG180, 4ACH180, 4AFJ304, 4B7T315, 4DIT316, 4J1R317, 
4J71317, 4NM0318, 4NM3318, 4NM5318, 4NM7318 and 4NU1318) with resolution of ≤ 3.0 Å (Figure 
3.37).  These structural files contain 77 kinase chains and used for calculating the conserved 
water molecules. We found 45 conserved water molecules with degree of conservation of 0.5 to 
0.9 (Figure 3.38). Five water molecules are located in the active site forming a network of 
hydrogen bonding with several amino acid residues including His179, Arg180, Asp181, Glu197, 
Asp200, Phe201, Gly202, Ser203, Ala204, and Cys218 (Figures 3.39-3.40). In this case the 
higher number of crystal structures signifies the results. The five conserved water molecules 
should be considered while performing the second step of virtual screening. 
 
Figure 3.37. Superimposed GSK-3β structures showing the conserved water molecules.  
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Figure 3.38. GSK-3β conserved water molecules. Waters are colored based on the degree of 
conservation from red to blue. 
 
Figure 3.39. GSK-3β conserved water molecules. There are five conserved active site waters 
having several hydrogen bonds with the surrounding amino acids. 
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Figure 3.40. GSK-3β conserved water molecules. The active site waters in the aligned 
structures. 
 
In case of PERK, we used 9 PDB structures (PDB codes: 4G31213, 4G34213, 4M7I214, 
4X7H214, 4X7J214, 4X7K214, 4X7L214, 4X7N214 and 4X7O214) with resolution of ≤ 3.0 Å (Figure 
3.41).  The PDB structural files contain 9 kinase chains. We used the kinase chains in calculating 
the conserved water molecules. The conserved water molecules in PERK were calculated as 28 
with degree of conservation of 0.66 to 1.00 (Figure 3.42). Four water molecules are located in 
the active site and involved in extensive hydrogen bonding with several amino acid residues in 
the ligand pocket including Gly599, Arg600, Lys621, Ile650, Val651, Asp936, Asn941, Val952, 
Gly953, Asp954, Phe955 and Gly956 (Figures 3.43-3.44). The four conserved water molecules 
will be considered while performing the second step of virtual screening. 
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Figure 3.41. Superimposed PERK structures showing conserved water molecules.  
 
Figure 3.42. PERK’s conserved water molecules. Waters are colored based on the degree of 
conservation from red to blue. 
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Figure 3.43. PERK’s conserved water molecules. There are four conserved active site waters 
having several hydrogen bonds with the surrounding amino acids. 
 
Figure 3.44. PERK’s conserved water molecules. The active site waters in the aligned structures. 
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3.3.3. Water mapping 
We scanned the ligand binding pockets for accommodation of water molecules using the 
thermodynamic properties of the different regions of the active site as a monitor. We used the 
homology models generated for CDK1 and GSK-3α in complex with one of the docking poses of 
our hit compounds. For CDK5, GSK-3β and PERK, we used their already solved crystal 
structures. We used SZMAP to define the region of the active site that can hold water with high 
and low residence. The positions in the active site that favors water molecules are suitable 
locations and allow room for polar ligand modifications. These water molecules if not in the 
stabilization regions of the protein, can be displaced with polar functional groups. Stabilization 
waters and waters allowed for displacement provide anchors for hydrogen bonds and 
electrostatic interactions with the polar substituents. The places of the active sites that are 
described as less thermodynamically stable positions for water molecules are suitable for non-
polar and hydrophobic modifications. Upon binding with ligands we observed changes in the 
thermodynamic properties of the active site change for ligand accommodation. Some water 
molecules were displaced with ligand functional groups. Some waters showed modified 
coordinates to participate in hydrogen bonds with ligand groups.  
In CDK1 we identified thermodynamically stable regions in the apoprotein structure 
(Figure 4.45). The water map shows large yellow surface, which indicates the high polarity of 
the active site. There are small patches of red surface close to the central part of αC-helix. The 
yellow surface represents the regions of high water occupancy, and the red regions for low water 
occupancy. Upon ligand binding, SZMAP represented only the regions of the water map, which 
are in contact with ligand. The polar groups flank perfectly with the yellow surface and the 
hydrophobic groups flank with the red surface (Figure 3.46). The regions of the active site that 
 
 
132 
show highest van der Waals interaction are found close to heterocyclic ring of the ligand and to 
αC-helix (Figure 3.47).  
From SZMAP calculations, there are 42 clusters of water molecules in the active site 
(Figure 3.48) with ∆G of 0.82 to -10.89 kcal/mol. About 16 water molecules are overlapping 
with the ligand atoms and displaced or modified the position to accommodate the ligand (Figure 
3.49). The water molecules that are predicted to be in the protein-ligand complex (33 waters with 
∆G of 0.76 to -11.13 kcal/mol) are displayed in Figure 3.50. The ligand binding pockets showed 
a chain of favorable and unfavorable water positions (Figure 3.51).   
The hydrophobic elements are unfavorable for ligand binding in the stable hydration site 
but are favorable in the unstable sites. However, the information inferred from each specific 
hydration site is based on the protein environment (Figure 3.52). For instance, the red water 
cluster (Figure 3.52) shows unstable hydration site with high ∆G and excess entropy. On the 
other hand this site shows strong hydrogen bonds to the surrounding amino acid residues 
(Leu134 and Ala145). This observation suggests the instability of hydrophobic group in this 
position and the activity is proposed to increase by adding polar group to displace this water 
molecule. In general, we defined 9 water molecules in an area of 5.00 Å around the ligand with 
occupancies ranging from 0.3 to 0.98 (Figure 3.53 and Table3.4). The ones with high entropy 
values are forming more contacts with the surrounding protein than with bulk water. The waters 
that show more negative ∆G are in stable hydration site and can be utilized either for lead 
optimization or target specificity. 
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Figure 3.45.  A thermodynamic map of CDK1. The regions of negative free energy are shown as 
yellow surface and the regions of positive free energy are shown as red surface. 
 
Figure 3.46. A thermodynamic map of CDK1 after ligand binding showing how the ligand 
interacts favorably or unfavorably with the amino acid residues in the active site. 
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Figure 3.47. The region of the active site of CDK1 that shows van der Waals interactions. 
 
Figure 3.48. The water clusters in CDK1. Water clusters overlapping with the ligand are 
displaced. Waters are colored according to ∆G 0.82 (red) to −10.89 (blue). 
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Figure 3.49. Waters clusters of CDK1 that are displaced due to ligand binding. Waters are 
colored according to ∆G −1.15 (red) to −7.67 (blue). 
 
Figure 3.50. Water clusters of CDK1 in the protein-ligand complex. Waters are colored 
according to ∆G from +0.76 (red) to −11.13 (blue). 
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Figure 3.51. The water chains in the active site of CDK1. Water clusters are shown as spheres, 
colored based on the ∆G value; from red (positive) to green (negative). Protein is displayed as 
cartoon with red α-helices, grey loops and cyan β-sheets. 
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Figure 3.52. Each hydration site provides specific knowledge based on the protein environment 
of CDK1. The red spheres (the unstable water clusters) participate in strong hydrogen bonding 
networks with the amino acid residues and can be displaced by hydrophilic groups. The green 
spheres (stable hydration sites) show strong hydrogen bonds with both Asp146 and Thr14, 
suggesting hydrophilic substitutions would improve the ligand activity. 
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Figure 3.53. The water sites within 5 Å distances of the ligands in CDK1.  
 
Table 3.4. Thermodynamic properties of water sites 5 Å around the ligands of CDK1. 
Site Occupancy ∆H -T∆S ∆G HB(W) HB(P) HB(L) 
W4 0.98 -7.36 5.02 -2.34 0.05 1.96 0 
W8 0.94 2.46 4.41 6.87 0.09 1.25 0 
W10 0.93 -1.23 3.88 2.65 1.48 0.97 0 
W23 0.81 -7.34 3.28 -4.06 1.16 1.06 0.91 
W61 0.42 -1.76 1.73 -0.03 0.6 1.85 0 
W73 0.36 0.36 0.98 1.34 2.45 0 0 
W75 0.34 7.01 0.99 8 0.84 0 0.05 
W81 0.32 -0.37 1.1 0.73 1.01 0.87 0 
W86 0.3 1.17 0.88 2.05 2.29 0 0 
HB: Hydrogen bonds, (W) with water, (P) with protein and (L) with ligand  
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We performed thermodynamic studies for other targets under investigation. We examined 
the crystal structure of CDK5 (4AU8289). CDK5 displayed a stable hydration site close to αC-
helix (Figure 3.54). There is continuous chain of stable waters in the active site suggesting the 
need of strong polar substituents. The thermodynamic characteristics of the ligand affect the 
regions of the watermap (Figure 3.55) to accommodate ligand binding. The regions of high van 
der Waals interactions are shown close to the N- and C-terminal of αC-helix (Figure 3.56). The 
water clusters are calculated in the apoprotein (Figure 3.57) to find out which water molecule 
will be displaced upon ligand binding (Figure 3.58). The distribution of waters is calculated in 
the protein-ligand complex (Figure 3.59).  
 
Figure 3.54. A thermodynamic map of CDK5. The regions of negative free energy are shown as 
yellow surface and the regions of positive free energy are shown as red surface. 
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Figure 3.55. A thermodynamic mapping of CDK5 after ligand binding showing how the ligand 
interacts favorably or unfavorably with the amino acid residues in the active site. 
 
Figure 3.56. The regions of the active site of CDK5 that show van der Waals interactions. 
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Figure 3.57. The water clusters in CDK5. Water clusters overlapping with the ligand are 
displaced. Waters are colored according to ∆G from +0.84 (red) to −8.59 (blue). Forty-five water 
sites are displayed. Three native waters within 5 Å of the ligand are shown as grey spheres 
 
Figure 3.58. Waters clusters of CDK5 that are displaced due to ligand binding. Waters are 
colored according to ∆G from +0.84 (red) to −6.35 (blue). Twelve water sites are displayed. 
Three native waters are shown as grey spheres. 
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Figure 3.59. Water clusters in the protein-ligand complex of CDK5. Waters are colored 
according to ∆G from 1.28 (red) to −10.18 (blue). A total of water sites are displayed. Three 
native waters are shown as grey spheres. 
 
We examined the active site of the homology model of GSK-3α, which showed stable 
hydration sites close to αC-helix (Figure 3.60) and small discrete patches of unstable sites in the 
ligand binding pockets. We observed a similar continuous chain of stable watermap in the active 
site as in case of CDK5, which recommends polar substituents in GSK-3α modulators. Upon 
ligand binding the hydration sites will accommodate the ligand by water displacement (Figure 
3.61). We observed small patches with van der Waals interactions around the ligand (Figure 
3.62). We calculated the water clusters in the apoprotein (Figure 3.63) to find out which water 
molecule will be displaced upon ligand binding (Figure 3.64). The water distribution in the 
active site was calculated in the protein-ligand complex (Figure 3.65). 
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Figure 3.60. A thermodynamic map of the GSK-3α model. The regions of negative free energy 
are shown as yellow surface and the regions of positive free energy are shown as red surface. 
 
Figure 3.61. A thermodynamic map after ligand binding to GSK-3α, showing how the ligand 
interacts favorably or unfavorably with the amino acid residues in the active site. 
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Figure 3.62. The regions of the active site of GSK-3α that show van der Waals interactions. 
 
Figure 3.63. The water clusters in the apoprotein of GSK-3α. Water clusters overlapping with 
the ligand are displaced. Waters are colored according to ∆G from −1.73 (red) to −11.21 (blue). 
A total of 32 water sites are displayed as spheres. Ligand is shown as sticks and protein as 
cartoon. 
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Figure 3.64. Waters clusters of GSK-3α that are displaced due to ligand binding. Waters are 
colored according to ∆G −2.08 (red) to −4.31 (blue). A total of 12 water sites are displayed.  
 
Figure 3.65. Water clusters in the protein-ligand complex of GSK-3α. Waters are colored 
according to ∆G from 0.78 (red) to −11.27 (blue). A total of 29 water sites are displayed.  
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We examined the binding pocket of the crystal structure of GSK-3β (PDB code: 
4ACC180). The ligand binding pockets of GSK-3β exhibited stable hydration sites close to αC-
helix, β1 and β2 strands (Figure 3.66). Small patches of unstable hydration sites are observed in 
the pocket. The water clusters forms a continuous chain of stable hydration sites. Polar functional 
groups are recommended in GSK-3β modulators. Ligand binding leads to water displacement 
(Figure 3.67). Two small patches with van der Waals interactions are around the ligand (Figure 
3.68). We calculated the water clusters in the apoprotein (Figure 3.69) to find out which water 
molecule might be displaced upon ligand binding (Figure 3.70). The water distribution in the 
active site was calculated in the protein-ligand complex (Figure 3.71). 
 
Figure 3.66. A thermodynamic map of GSK-3β. The regions of negative free energy are shown 
as yellow surface and the regions of positive free energy are shown as red surface. 
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Figure 3.67. A thermodynamic mapping of GSK-3β after ligand binding showing how the ligand 
interacts favorably or unfavorably with the amino acid residues in the active site. 
 
Figure 3.68. The regions of the active site of GSK-3β that show van der Waals interactions. 
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Figure 3.69. The water clusters of GSK-3β. Water clusters overlapping with the ligand are 
displaced. Waters are colored according to ∆G from −1.51 (red) to −10.74 (blue). A total of 47 
water sites are displayed as spheres. Ten native waters are shown as grey spheres. Ligand is 
shown as sticks and protein as cartoon. 
 
 
 
 
149 
 
Figure 3.70. Waters clusters of GSK-3β that are displaced due to ligand binding. Waters are 
colored according to ∆G from −1.86 (red) to −5.17 (blue). Twelve water sites are displayed. Ten 
native waters are shown as grey spheres. 
 
Figure 3.71. Water clusters in the protein-ligand complex of GSK-3β. Waters are colored 
according to ∆G from −1.5 (red) to −10.72 (blue). Twenty-nine water sites are displayed. Ten 
native waters are shown as grey spheres. 
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We studied the binding pocket of the crystal structure of PERK (PDB code: 4G31213). 
The ligand binding pockets PERK exhibited stable hydration sites close to αC-helix (Figure 
3.72). Small patches of unstable hydration sites are observed in the pocket close to the middle 
part of αC-helix. The watermap forms a broken chain of stable hydration sites. Polar and non-
polar functional groups are recommended for PERK modulators. Ligand binding leads to water 
displacement (Figure 3.73). Three small patches of high van der Waals interactions are around 
the ligand (Figure 3.74). We calculated the water clusters in the apoprotein (Figure 3.75) to find 
out which water molecule will be displaced upon ligand binding (Figure 3.76). The water 
distribution in the active site was calculated in the protein-ligand complex (Figure 3.77). 
 
Figure 3.72. Thermodynamic map of PERK. The regions of negative free energy are shown as 
yellow surface and the regions of positive free energy are shown as red surface. 
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Figure 3.73. Thermodynamic map of PERK after ligand binding, showing how the ligand 
interacts favorably or unfavorably with the amino acid residues in the active site. 
 
Figure 3.74. The regions of the active site of PERK that show van der Waals interactions. 
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Figure 3.75. The water clusters in PERK. Water clusters overlapping with the ligand are 
displaced. Waters are colored according to ∆G from 1.48 (red) to −10.79 (blue). Thirty-eight 
water sites are displayed as spheres. Five native waters are shown as grey spheres. Ligand is 
shown as sticks and protein as cartoon. 
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Figure 3.76. Waters clusters of PERK, which were displaced due to ligand binding. Waters are 
colored according to ∆G from −1.58 (red) to −5.95 (blue). Ten water sites are displayed. Five 
native waters are shown as grey spheres. 
 
Figure 3.77. Water clusters in the protein-ligand complex of PERK. Waters are colored 
according to ∆G from 2.16 (red) to −10.79 (blue). Thirty-five water sites were displayed. Five 
native waters are shown as grey spheres. 
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To improve the binding affinity of GSK2606414213 (Figure 3.78) with PERK, several 
modifications can be attempted such as adding polar (Figures 3.79 and 3.80), or small non-polar 
substituents on the phenyl ring. Also, polar substituent on the yellow sites of the indole (Figure 
3.80) will improve the binding. 
 
Figure 3.78. The ligand binding pockets of PERK showing GSK2606414 as large sticks and the 
surrounding amino acid residues are displayed as sticks. 
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Figure 3.79. Left, the neutral free energy difference grid at the coordinate of the ligand. The 
energy ranges from orange  (favorable for polar) to purple (favorable for non-polar). Middle, 
matching and mismatching of the ligand with the thermodynamics of the active site. The ligand 
matches the active site properties, some groups are more favorably should be hydrophobic but in 
general there is no mismatch. Left, the regions of the ligand (spheres) that can accommodate 
polar substituents to improve the binding affinity. 
 
Figure 3.80. Left, the regions of the ligand that 
accommodate non-polar substituents such as F and CH3. 
Right, the regions that accommodate other types of non-
polar substituents. 
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3.4. Summary 
We studied the common structural motifs and domains of GSK-3β, CDK5 and PERK 
using the Conserved Domain Database. The identified common structural features included G-
loop, αC-helix, hinge region, HRD domain, activation loop and DFG region. Further, we 
identified the conserved water molecules in GSK-3β, CDK5 and PERK through calculating the 
degree of water conservation by superimposing the crystal structures of the kinase domains using 
the backbone as the frame reference. Furthermore, we analyzed the thermodynamic properties of 
the ligand-binding pocket of CDK1, CDK5, GSK-3α, GSK-3β and PERK. We were able to 
define the regions of the active site that can accommodate water molecules. These water 
molecules, if not in the stabilization regions of the protein, could be displaced upon ligand 
binding. The locations in the active site that favor water molecules are suitable places for ligand 
modifications with polar functional groups. The places of the active sites that were described as 
less thermodynamically stable positions for water molecules should be suitable for non-polar and 
hydrophobic modifications. Stabilization waters and displaceable waters provided clues for 
possible hydrogen bonds and electrostatic interactions with small molecules. 
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CHAPTER 4. STUDY OF THE PROTEIN-LIGAND INTERACTIONS OF CDK1, CDK5, 
GSK-3α, GSK-3β AND PERK USING MOLECULAR DYNAMICS SIMULATIONS 
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4.1. Introduction 
In this chapter, we investigated the protein-ligand interactions of CDK1, CDK5, GSK-3α, 
GSK-3β and PERK using molecular dynamic (MD) simulations. We studied the important 
interactions that significantly affect ligand binding to protein targets including hydrogen bonds, 
hydrophobic, ionic, π-cation, π-π contacts and interactions through and involving water bridges. 
Ligands properties such as intramolecular hydrogen bond formation, solvent accessible surface 
area and polar surface area were calculated.  
Since binding with a regulatory protein is essential for CDK5 activity319, we also studied 
the protein-protein interaction profile of CDK5 with its regulatory subunit. P35 is most well 
studied CDK5 regulatory protein. It is a 35-kDa protein and consists of 307 amino acids. Studies 
showed that p35 could be divided into two regions named p10 and p25. The p25 region is the C-
terminal and comprises 209 amino acids. P25 is a stronger CDK5 activator because it has longer 
half-life than P35 and it is more cellular localized319. High calcium concentration associated with 
deposition of Aβ activates the cleavage of p35 to p25, resulting in the formation of the 
hyperactive CDK5/p25 complex. In this study, we reported the protein-protein interactions 
between CDK5 and p25. Small molecules, which target this interaction, may provide a potential 
therapeutic benefit for AD319.  
In these studies, we used the 3D models that were prepared for CDK1 and GSK-3α (cf. 
Chapter 2). In case of the other kinases we utilized an X-ray crystal structures [for CDK5 (PDB 
code: 3O0G145), for GSK-3β (PDB code: 4ACC180) and for PERK (PDB code: 4G31213)]. We 
decided to use a protein-ligand complex for each enzyme in order to define their interaction 
profiles.  
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4.2. Methods 
4.2.1. Protein structure preparation. 
The protein-ligand complexes were prepared using the Protein Preparation Wizard of 
Schrödinger package294, 295. For the crystal structures we retained the water molecules within 5 Å 
around the bound ligand. Missing hydrogen atoms were added, bond orders were corrected, and 
missing side chains and loops were completed using Prime217-219. Water orientations were 
sampled and hydrogen bonds were assigned. The structures were subjected to a series of energy 
minimizations using OPLS2005 force field. The IMPACT module was used for structure 
refinement till the RMSD of the heavy atoms converged to 0.3 Å.  
 
4.2.1. MD simulations 
DESMOND320-323 software was used for the MD simulations. We used the OPLS-2005 
force field. The protein structures were solvated with a TIP4P water model in orthorhombic 
simulation box with dimensions of 90 Å x 90 Å x 9 Å. The calculated numbers of solvent 
molecules were 10,047, 10810, 12940, and 10345 for CDK1, GSK-3α, GSK-3β and PERK 
correspondingly. Sodium ions were added based on the total charge of each protein. In case of 
CDK5, we built three systems. One was for the kinase domain and it had 10052 solvent 
molecules. Another system was for the p25 and we added 6022 solvent molecules. The third 
system was for the CDK5-p25 complex with 13903 solvent molecules. Adding an appropriate 
number of Na+ ions neutralized the net charge on the protein. The solvated proteins were then 
energy-minimized with the DESMOND minimization algorithm with 5000 iterations and 
convergence threshold of 1.0 kcal/mol/Å. Short MD simulations were performed before the 
production step to achieve further structural relaxation of the minimized proteins. The relaxation 
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step was 24 ps, and was performed using the NPT ensemble324 at a temperature of 300º K. The 
production step was executed using the NPT ensemble, the Nosé−Hoover chain thermostat325, 
and the Martyna−Tobias−Klein barostat326. A time step of 1 fs was used for the RESPA 
integrator. The short range Coulombic interactions cutoff was set to 9 Å and the Particle Mesh 
Ewald method327 was used to treat the long-range electrostatics. The M_SHAKE algorithm320-323 
was used to constrain the hydrogen bonds. The snapshots (frames) were saved at intervals of 4.8 
ps. The production step was carried out for 5 ns for each kinase under investigation and for 50 ns 
for CDK5 and for the CDK5/p25 complex to obtain enough information about their protein-
protein interaction profile. We monitored the MD simulations for each protein structure under 
investigation to get insights into protein structural conformation. 
 
4.3. Results and discussion 
The calculated Root Mean Square Deviation (RMSD) of the protein backbones during the 
course of MD320-323 was 1-3 Å (Figures 4.1-4.5), which is acceptable for small, globular proteins. 
RMSD is employed for measuring the atoms’ movement average of variation for each frame 
with regard to the initial geometry. The formula used for calculating RMSD for frame x is the 
following: 
𝑅𝑀𝑆𝐷. = 	 1𝑁 𝑟&K 𝑡. −	 𝑟& 𝑡M91 *	N&O) 	
where N is the number of atoms; tref is the reference time (first frame was considered as the 
reference in our calculations and so reference time was t=0); and r' is the location of the atoms in 
frame x after superposition on the first frame, where frame x is reported at time tx. This is 
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repeated for all frames in the simulation trajectory.  
 
Figure 4.1.  The protein–ligand RMSD plots of CDK1.  The figure shows the RMSD (on the 
right Y-axis) for Cα's, side chains and heavy atoms (all atoms but not hydrogens). The Cα plot 
shows the RMSD change of the protein (on the left y-axis) by aligning CDK1 MD frames on the 
Cα's of the initial conformation. The ligand RMSD was calculated to check the stability of the 
ligand in the binding pocket of CDK1. In the Ligand versus Protein plot, the RMSD of the ligand 
heavy atoms were calculated by the placement of the CDK1–ligand complex on the CDK1 
backbone of the first frame. The observed Ligand versus Protein RMSD values are lower than 
those of the CDK1 backbones, which means the ligands are stable inside the binding sites. To 
measure the internal fluctuation of ligand atoms inside the binding site, we plot Ligand versus 
Ligand, which shows the RMSD of a ligand after superposition on its initial conformation. 
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Figure 4.2. The protein–ligand RMSD plots for CDK5. The figure shows the RMSD for Cα's, 
side chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot. 
 
Figure 4.3. The protein–ligand RMSD plots of GSK-3α.  The figure shows the RMSD for Cα's, 
side chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot. 
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Figure 4.4. The protein–ligand RMSD of GSK-3β. The figure shows the RMSD for Cα's, side 
chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot. 
 
Figure 4.5. The protein–ligand RMSD of PERK. The figure shows the RMSD for Cα's, side 
chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot. 
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 We calculated the Root Mean Square Fluctuation (RMSF) of the protein because it is 
beneficial in describing the local changes along the protein chain and this allowed us to monitor 
the regions of the proteins that mostly fluctuated during the course of MD simulations (Figures 
4.6-4.10). The N- and C-terminal fluctuated the most compared to any other part of the protein. 
The structured regions of the protein such as α helices and β strands were less fluctuating than 
the unstructured part  (loops) of the protein. 
The RMSF320-323 can be calculated by the following formula: 
𝑅𝑀𝑆𝐹& = 	 1𝑇 < 𝑟&K 𝑡 −	 𝑟& 𝑡M91 * >	TUO)  
where T is the trajectory time over which the RMSF is calculated, tref is the reference time, ri is 
the position of residue i on frame (t); r' is the position of atoms in residue i on the reference 
frame, and the angle brackets indicate that the average of the square distance is taken over the 
selection of atoms in the residue.  
 
Figure 4.6. RMSF plot for CDK1. The figure shows the RMSF for Cα's, backbone, side chains 
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green 
vertical bars. 
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Figure 4.7. RMSF plot of CDK5. The figure shows the RMSF for Cα's, backbone, side chains 
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green 
vertical bars. 
 
Figure 4.8. RMSF plot of GSK-3α. The figure shows the RMSF for Cα's, backbone, side chains 
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green 
vertical bar. 
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Figure 4.9. RMSF plot of GSK-3β. The figure shows the RMSF for Cα's, backbone, side chains 
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green 
vertical bars. 
                       
Figure 4.10. RMSF plot of PERK. The figure shows the RMSF for Cα's, backbone, side chains 
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green 
vertical bars. 
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Then, we monitored the protein secondary structure elements (SSE) including α-helices 
and β-strands throughout the development of MD simulation (Figure 4.11-4.15). Residues of 
each protein were plotted with regard to the SSE distribution. The % helix, % strand, and % total 
SSE for CDK1 were 24.37, 15.01, and 39.38, respectively. Those of CDK5 were 35.54, 8.51, and 
44.05 respectively. Those of GSK-3α were 25.24, 16.15, and 41.39 respectively. Those of GSK-
3β were 23.80, 16.07, and 39.86 respectively. Those of PERK were 30.57, 17.02, and 47.59 
respectively. We monitored the SSE composition for each frame over the course of the 
simulation (Figure 4.16) and the assignment of the SSE of each residue over time (Figure 4.16). 
 
	
Figure 4.11. The SSE distribution of CDK1. Cyan represents strands and orange represents 
helices. The % helix, % strand, and % total SSE for CDK1 were 24.37, 15.01, and 39.38, 
respectively. 
 
 
Figure 4.12. The SSE distribution of CDK5. Cyan represents strands and orange represents 
helices. The % helix, % strand, and % total SSE were 35.54, 8.51, and 44.05, respectively. 
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Figure 4.13. The SSE distribution of GSK-3α. Cyan represents strands and orange represents 
helices. The % helix, % strand, and % total SSE were 25.24, 16.15, and 41.39, respectively. 
 
 
 
Figure 4.14. The SSE distribution of GSK-3β. Cyan represents strands and orange represents 
helices. The % helix, % strand, and % total SSE were GSK-3β were 23.80, 16.07, and 39.86, 
respectively. 
 
 
 
Figure 4.15. The SSE distribution of PERK. Cyan represents strands and orange represents 
helices. The % helix, % strand, and % total SSE were 30.57, 17.02, and 47.59, respectively. 
 
 
169 
 
 
Figure 4.16. SEE composition of 
CDK1 (first row, left), CDK5 (first 
row, right), GSK-3α (second row, 
left), GSK-3β (second row, right) and 
PERK (third row). 
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We examined the Ligand Root Mean Square Fluctuation (L-RMSF) by measuring the 
position variations of all ligand's atoms. The ligand RMSF offers understandings on the energetic 
effect of ligand functional groups on protein binding. The Fit Ligand on Protein (Figures 4.17-
4.21) signifies the ligand atoms’ fluctuation and was calculated by fitting the protein-ligand 
complexes on the protein backbones to measure ligand heavy atoms’ RMSF. To quantify the 
internal atom fluctuation, the ligand in each frame is overlaid on the ligand in the first frame 
followed by measuring the RMSF of ligand heavy atoms. The RMSF320-323 for atom i is 
calculated by the following formula:  
𝑅𝑀𝑆𝐹& = 	 1𝑇 𝑟&K 𝑡 −	 𝑟& 𝑡M91 *	TUO)  
where T is the MD simulation time, tref is the reference time, r is the position of atom i in the 
reference at time tref, and r' is the position of atom i at time t after superposition on the reference 
frame. 
We inspected the protein-ligand contacts throughout the progression of the simulations. 
Four types of interactions were observed namely hydrogen bonds, hydrophobic, ionic and water 
bridges. H-bonds fall into four groups: backbone acceptor; backbone donor; side-chain acceptor 
and side-chain donor.  
H-bonds play an obvious part in ligand binding and this sort of interaction is a well-
considered property in drug design due its effect on drug selectivity and biotransformation. To 
monitor H-bonds between ligand and protein we set up the distance between the donor and 
acceptor atoms (D—H···A) to be less than 2.5Å. The donor-hydrogen-acceptor (D—H···A) 
angle was set up to be ≥120° and ≥90°.  
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The second important interactions are hydrophobic contacts that are of three subtypes: π-
cation, π-π, and other non-specific interactions. Usually these interactions take place between 
hydrophobic ligand fragment and a hydrophobic amino acid and/or an aromatic (Figure 4.22-
4.26). 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. L-RMSF of the CDK1 ligand. The 2D ligand structure with atom labels is shown 
above. The 'Fit Ligand on Protein' line shows the ligand fluctuations with respect to the protein. 
The protein–ligand complex is first aligned on the protein backbone and then the ligand RMSF is 
measured on the ligand heavy atoms. 'Ligand' line shows fluctuations where the ligand in each 
frame is aligned on the ligand in the reference frame, and its fluctuations are measured for the 
ligand heavy atoms. These RMSF values reflect the internal atom fluctuations of the ligand. 
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Figure 4.18. L-RMSF of the CDK5 ligand. The 2D ligand structure with atom labels is shown 
above. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19. L-RMSF of the GSK-3α ligand. The 2D ligand structure with atom labels is shown 
above. 
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Figure 4.20. L-RMSF of the GSK-3β ligand. The 2D ligand structure with atom labels is shown 
above. 
 
 
 
 
 
 
 
 
 
Figure 4.21. L-RMSF of the PERK ligand. The 2D ligand structure with atom labels is shown 
above. 
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We considered π-cation interaction between an aromatic and charged groups if the 
distance between the groups is within 4.5 Å. π-π interactions are monitored when two aromatic 
groups stacked face-to-face or face-to-edge. Other non-specific hydrophobic interactions take 
place when side chain within 3.6 Å of a ligand's aromatic or aliphatic carbons. Ionic interactions 
should occur within of 3.7 Å between two oppositely charged atoms. Water bridges are 
hydrogen-bonded protein-ligand interactions mediated by a water molecule. The geometry 
criteria of water bridges are a distance of 2.7 Å between the donor and acceptor atoms (D—
H···A); a donor angle of ≥110° between the donor-hydrogen-acceptor atoms (D—H···A); and an 
acceptor angle of ≥80° between the hydrogen-acceptor-bonded atoms (H···A—X). 
 
Figure 4.22. Protein–ligand contacts of the CDK1 complex. The chart is standardized over the 
course of simulation with a value of 0.8, for example, meaning that for 80% of the simulation 
time the specific interaction is conserved. 
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                          Figure 4.23. Protein–ligand contacts of the CDK5 complex. 
 
                          Figure 4.24. Protein–ligand contacts of the GSK-3α complex. 
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                      Figure 4.25. Protein–ligand contacts of the GSK-3β complex. 
 
 
                             Figure 4.26. Protein–ligand contacts of the PERK complex. 
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All interactions that occur more than 10% of the simulation time are represented (Figures 
4.27-4.31). CDK1 shows H-bond of 100%, 95% and 58% between Glu81, Leu83 and Lys33 and 
ligand. In CDK5, Cys83, Glu81 and Phe80 form H-bonds with 87%, 72% and 36%. GSK-3α 
shows H-bonds between the following amino acids and ligand: Lys30 with 90% and Arg86 with 
49%, Thr83, Pro81, and Gln17 through water bridges with 57%, 52%, and 30% respectively. 
GSK-3β exhibits H-bonds with Asp133 of 92%, and Lys85 of 73%. PERK shows H-bonds with 
Gln888 of 99%, and Cys890 of 97%, and with Val651 and Val952 through water bridges of 69% 
each. 
     
Figure 4.27. Protein–ligand contacts of CDK1 
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        Figure 4.28. Protein–ligand contacts of CDK5 
 
 
179 
 
Figure 4.29. Protein–ligand contacts of GSK-3α 
		
Figure 4.30. Protein–ligand contacts of GSK-3β 
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Figure 4.31. Protein–ligand contacts of PERK 
 
We also studied a timeline demonstration of the interactions and contacts for each protein 
(Figures 4.32-4.36). Some of the interacting residues show more than one specific contact with 
the ligand. A dial plot accompanies each rotatable bond and bar plots of the same color. We used 
the ligand torsions to monitor the conformational evolution of every rotatable bond in the ligand 
during the simulation trajectory. Dial plots describe the torsional conformation throughout the 
course of the simulation with the beginning of the simulation is in the center and the time 
evolution is plotted radially outwards. The bar plots summarize the data on the dial plots, by 
showing the probability density of the torsion (Figures 4.38-3.41). 
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Figure 4.32. Protein–ligand timeline representation of CDK1. The top section shows the entire 
number of the contacts protein makes with ligand over the progression of simulation. The bottom 
section shows residues interacting with the ligand in each trajectory frame. 
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               Figure 4.33. Protein–ligand interaction timeline representation of CDK5. 
 
            Figure 4.34. Protein–ligand interaction timeline representation of GSK-3α. 
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            Figure 4.35. Protein–ligand interaction timeline representation of GSK-3β. 
 
         Figure 4.36. Protein–ligand interaction timeline representation of PERK. 
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Figure 4.37. A 2D schematic representation of the ligand in CDK1 is shown with color-coded 
rotatable bonds.  
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Figure 4.38. A 2D schematic representation of the ligand in CDK5, using radial and bar plots. 
 
 
186 
 
                
           
Figure 4.39. A 2D schematic representation of the ligand in GSK-3α, using radial and bar plots 
 
 
187 
   
                        
                     
Figure 4.40. A 2D schematic representation of the ligand in GSK-3β, using radial and bar plots 
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Figure 4.41. A 2D schematic representation of the ligand in PERK, using radial and bar plots 
We monitored the ligand properties throughout the course of simulation such as ligand RMSD 
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with respect to the reference conformation, radius of Gyration (rGyr) to quantify the 
'extendedness' of the ligand, ligand intramolecular hydrogen bonds (intraHB), molecular surface 
area (MolSA) (equivalent to a van der Waals surface area), solvent accessible surface area 
(SASA), and polar surface area (PSA) (Figures 4.42-4.46). SASA is the surface area of the 
ligand, which is accessible by water molecules while PSA is SASA of the ligand, which is only 
controlled by oxygen and nitrogen atoms. 
 
 
Figure 4.42. Ligand properties of CDK1 
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                             Figure 4.43. Ligand properties of CDK5 
 
                       Figure 4.44. Ligand properties of GSK-3α 
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                     Figure 4.45. Ligand properties of GSK-3β 
 
                          Figure 4.46. Ligand properties of PERK 
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We studied the protein-protein interaction between CDK5 and p25, and averaged their 
contacts throughout the course of the 50 ns simulations. CDK5 (PDB code: 3O0G) is a dimer of 
kinase-p25 complex. In our study we used one kinase chain (chain B) and one p25 chain (chain 
E). The interacting amino acids are selected in a threshold distance of 8 Å. The contacts between 
the kinase and p25 are checked before and after simulations and more than 70% of the contacts 
were found to be preserved in all trajectory frames, which are not necessarily existed in the 
reference. We are presenting here the contacts between the kinase domain and p25 (Figure 4.47), 
the interaction overview (Table 4.1), H-bonds of the reference frame (Table 4.2) and of the 
average frames (Table 4.3) and the contact maps (Figure 4.48) 
 
Figure 4.47. The kinase domain is shown as violet surface and p25 as pink surface. The interface 
is shown in dark color. 
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Table 4.1. Interaction overview between the kinase domain and p25. 
Title  Value 
Number of interacting residues chain B 54 
Number of interacting residues chain E 60 
Number of hydrophilic-hydrophobic interactions 145 
Number of hydrophilic-hydrophilic interactions 101 
Number of hydrophobic-hydrophobic interactions 72 
 
Table 4.2. H-Bonds of the reference frame. 
Acceptor Donor Dist* Type 
Res1 Atom Chain Res2 Atom Chain H-Bonds Cat* Dist† 
SER46 OG B SER235 OG E 2.65 SS 5.39 
SER47 OG B ILE241 O E 2.33 SM 6.08 
ARG149 NH1 B MET237 O E 3.18 SM 7.75 
ARG149 NH2 B MET237 O E 3.05 SM 7.75 
CYS157 SG B ASN239 OD1 E 3.64 SS 7.00 
SER235 OG E SER46 OG B 2.65 SS 5.39 
SER269 OG E GLU57 OE2 B 2.58 SS 7.28 
Dist* Distance between donor and acceptor atoms in Å. Dist† Distance between Cα atoms of the 
interacting residues in Å. Cat* category, SS: sidechain to sidechain H-bond, SM: sidechain 
mainchain H-bond. 
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Table 4.3. Average H-Bonds of all frames. 
Acceptor Donor Dist* Type 
Res1 Atom Chain Res2 Atom Chain H-Bonds Cat* Dist† 
LYS254 NZ E ASP38 OD2 B 2.55 SS 11.09 
SER242 OG E VAL44 O B 2.92 SM 5.83 
ARG50 NE B SER235 O E 2.95 SM 6.08 
ARG50 NH2 B GLU240 O E 2.69 SM 11.22 
LYS56 NZ B SER269 OG E 2.92 SS 7.14 
SER269 OG E GLU57 OE2 B 2.73 SS 6.86 
ASN121 ND2 B ALA277 O E 3.11 SM 5.00 
ARG149 NH1 B MET237 O E 2.91 SM 5.29 
GLY152 N B ASN276 OD1 E 2.85 MS 3.87 
ILE153 N B ASN276 OD1 E 3.02 MS 6.16 
Dist* Distance between donor and acceptor atoms in Å. Dist† Distance between Cα atoms of the 
interacting residues in Å. Cat* category, SS: sidechain to sidechain H-bond, SM: sidechain 
mainchain H-bond, MS: mainchain sidechain H-bonds. 
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Figure 4.48. Contact maps of the kinase domain (chain B) and p25 (chain E). All amino acids 
that are within the cutoff distance are displayed with distance color-codes (left). All interacting 
amino acids within an 8 Å cutoff are shown, color-coded based on the interaction property 
(right). 
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4.4. Summary 
We defined the protein-ligand interaction profiles of CDK1, CDK5, GSK-3α, GSK-3β 
and PERK operating MD simulations, which provided a time-dependent study of the interactions 
and contacts for each ligand. These interactions included hydrogen bonds, hydrophobic, ionic, 
water bridges, π-cation interaction and π-π interactions. We used the 3D models that we 
generated for CDK1 and GSK-3α, and experimental X-ray crystal structures of CDK5, GSK-3β 
and PERK. We monitored the ligand properties throughout the course of MD simulation 
including intraHB, MolSA, SASA, and PSA. In addition, we described the protein-protein 
interactions between CDK5 and p25 and reported all interacting amino acids that are within a 
distance of 8 Å. Small molecules which target this interaction may offer a therapeutic benefit for 
AD.  
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CHAPTER 5. VIRTUAL SCREENING TO FIND INHIBITORS OF PROTEIN KINASES TO 
MANAGE ALZHEIMER’S DISEASE 
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5.1. Introduction 
We are interested in developing new AD hits by targeting some of the kinases 
significantly involved in the disease; these would be kinases that are involved in the four primary 
processes relevant to the neurodegeneration found in AD, including APP processing, tau 
hyperphosphorylation, neuroinflammation, and neurotoxicity. The protein kinases such as 
GSK3α/β, PKC-ε, PERK, CDK1 and CDK5 are involved in tau hyperphosphorylation, APP 
processing, and apoptosis. Our main intention in this chapter was to screen for inhibitors of the 
protein kinases involved in AD pathogenesis. We constructed a non-redundant database from the 
commercially available ZINC database through filtering the database using multiple drug-like, 
functional groups and physicochemical properties filters. The constructed database was used in a 
ligand-based virtual screening approach to find new PERK inhibitors using the bioactive 
conformation of GSK2606414213 and based on the 3D Shape similarity searching and pose fitting 
approaches. We also performed a protein structure-based virtual screening to find multiple-
kinase (CDK1, CDK5, and GSK-3α/β inhibitors through a parallel docking approach. In 
addition, we defined two possible bryostatin 1 PKC-ε binding pockets, with druggability scores 
of 0.59 and 0.47 using fpocket283 (a geometry-based cavity detection algorithm). We checked the 
binding mode of bryostatin 1 in both pockets (using the FRED exhaustive search docking 
algorithm) and it showed good fitting into both pockets with comparable ChemGauss4 scores (–
8.1 and –7.9). We used these structural findings as the basis for screening a library of compounds 
in order to find new potent and selective PKC-ε activators. 
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5.2. Methods 
5.2.1. Database collection 
 We used the ZINC databases328 of small organic molecules and natural products in the 
virtual screening. ZINC (acronym for ZINC is not commercial) is a free database for ligand and 
structure based virtual screenings that contains more than 22 Million compounds in 3D format. 
ZINC uses 10 vendor catalogs for the compounds’ source including ChemBridge, ChemDiv, 
Ryan, Asinex, Sigma-Aldrich, Maybridge, Specs, Comgenex, and Otava. All purchasable ZINC 
databases of small molecules were downloaded from http://zinc.docking.org/subsets/all-
purchasable in SDF format (~22 Million compounds).   
 Because of the fact that over a third of all drugs are natural products329 or similar to 
natural products, we decided to use also the ZINC database of natural products. We downloaded 
the compounds from http://zinc.docking.org/browse/catalogs/natural-products in SDF format and 
we ended up with a total number of compounds of 166210 grouped based on their vendors as 
follow: AfroDb Natural Products (885 compounds), Ambinter Natural Products (36057 
compounds), AnalytiCon Discovery NP (11247 compounds), Herbal Ingredients In-Vivo 
Metabolism (663 compounds), Herbal Ingredients Targets (802 compounds), IBScreen NP 
(74940 compounds), Indofine Natural Products (144 compounds), NPACT Database (1423 
compounds), Nubbe Natural Products (588 compounds), Princeton NP (14084 compounds),  
Selleck BioChemicals NP (136 compounds), Specs Natural Products (651 compounds), TCM 
Database @ Taiwan (24117 compounds), and UEFS Natural Products (473 compounds). 
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5.2.2. Database filtration 
 The molecular structures of ZINC databases328 were filtered to discard all structures that 
do not fulfill the drug-likeness properties and eliminate compounds that may adversely affect 
human body. Generally, we performed two major database filtration steps: (state the two here). 
 
5.2.2.1. Drug-like filters 
 The stereochemical features of each structure were provided from the source. Before 
generation of the 3D structures and multiple-conformers of each molecule, we filtered out all 
metabolically-unstable or metabolically-unfavorable structures. We kept only structures that 
fulfill our specified drug-like properties (Table 5.1). The databases were filtered using the filter 
module of OpenEye Scientific software (embedded in OMEGA)330-334. Several physicochemical 
properties and functional groups rules were designated to prepare our non-redundant database of 
drug-like compounds (Table 5.1). 
 
Table 5.1. Physicochemical properties used for database filtration. 
Property Filter Limit 
Minimum molecular weight 200.0 
Maximum molecular weight 700.0 
Minimum number of heavy atoms 15.0 
Maximum number of heavy atoms 35.0 
Minimum number of ring systems 0.0 
Maximum number of ring systems 5.0 
Minimum atoms in any ring system 0.0 
Maximum atoms in any ring system 20.0 
Minimum number of rotatable bonds 0.0 
Maximum number of rotatable bonds 20.0 
Minimum number of rigid bonds 0.0 
Maximum number of rigid bonds 35.0 
Minimum number of hydrogen-bond donors 0.0 
Maximum number of hydrogen-bond donor 6.0 
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Minimum number of hydrogen-bond acceptors 0.0 
Maximum number of hydrogen-bond acceptors 10.0 
Minimum number of hydrogens on O & N atoms 0.0 
Maximum number of hydrogens on O & N atoms 5.0 
Minimum number formal charges 0.0 
Maximum number of formal charges 3.0 
Minimum sum of formal charges -2.0 
Maximum sum of formal charges 2.0 
Minimum chiral centers 0.0 
Maximum chiral centers 5.0 
Minimum XLogP 1.0 
Maximum XLogP 4.0 
Minimum solubility Moderately 
Maximum number of Lipinski violations 1.0 
 
5.2.2.2. Removing molecules with undesirable functional groups 
 Based on functional group knowledge, undesirable functional groups were removed.  
These functional groups included toxic functionalities, groups with a high chance of binding 
covalently with biological targets, groups that may affect with the experimental assay, and 
groups of low likelihood of oral bioavailability.  
 
5.2.3. Generation of multiple conformers  
 The conformational search was performed using OMEGA of OpenEye software330-334. 
OMEGA provides three force fields; the MMFF94s force field (the 94s variant of the Merck 
Molecular force Field), the MMFF94s_NoEstat force field (includes all MMFF94s terms except 
Coulomb interactions) and the MMFF94s_Trunc force field (includes all MMFF94s terms except 
Coulomb interactions and the attractive part of Van der Waals interactions). OMEGA performs 
conformer generation through two stages: model building (initial molecular structures are 
generated using fragment templates) and torsion search (conformers generation based on torsion 
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angles and connection between fragments). We generated multiple conformers’ database using 
the following parameters. 
 
5.2.3.1. Force field 
 We used MMFF94s_NoEstat (the 94s variant of Merck molecular force field excluding 
the columbic terms from the MMFF94s force field) as the build and search fore fields. 
 
5.2.3.2. Energy window 
 We used an energy window of 10 kcal/mol as the maximum allowed energetic separation 
from the lowest conformer energy in the model building and torsion search stages. Any 
conformer that has calculated strain energy less than the sum of the energy window and the 
energy of the global minimum conformer was accepted. Higher energy conformers were 
discarded. 
 
5.2.3.3. Root Mean Square Deviation (RMSD) and rotatable bonds 
 We specified the Cartesian distance (RMSD) below which two conformers are 
considered duplicates as 0.5 Å. The maximum number of rotatable bonds was set to -1 to allow 
for no maximum limit. 
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5.2.3.4. Maximum number of conformers 
 The maximum number of conformations to be generated was set to zero to allow for 
generation of all possible conformers within the specified energy window and RMSD. All 
generated conformers were written to the output file. Duplicates were removed. 
 
5.2.3.5. Structure enumeration 
We allowed for enumeration of pyramidal invertible nitrogen geometries, and ring 
conformers. We did not consider for sampling the hydrogen positions for -OH, -SH, and amines. 
 
5.2.4. 3D similarity search 
 In our study we performed a 3D similarity search using a combined 3D shape model and 
pharmacophoric elements of the bioactive conformer of GSK2606414213. We carried out the 
study according to the following steps: 
 
5.2.4.1. 3D similarity model construction 
The bioactive conformer of GSK2606414213 was extracted from the crystal structure of 
the protein kinase RNA-like endoplasmic reticulum kinase (PERK; PDB ID: 4G31213) by using 
Openeye software335, 336. 3D shape query with color atoms (pharmacophoric elements) was 
constructed by vROCS335, 336. We used ligand model builder to create the shape query, allowing 
more than model to be generated and merging the color atoms with the 3D shape to assure that 
the shape query codes both molecular shape and chemical features. We used Mills Dean force 
field as the color force field to build and then measure chemical similarity between the query and 
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the molecular database and as well to refine the shape-based overlays in the similarity search 
step335, 336. In general, the color force field file describes color atoms type to specify: which 
functional groups the color atoms should be applied to (hydrogens are ignored), and the type of 
interaction between color atoms (attractive or repulsive). The color features include: donor such 
as acid-OH, acceptor such as carboxylate, anion such as tetrazole, cation as guanidinium, 
hydrophobe as alkyl groups, and rings which are of defined size e.g. 4-7 atoms. 
 
5.2.4.2. 3D similarity model validation 
 We constructed a dataset of actives and decoys based on the reported IC50 values for the 
purpose of statistically validating the query for its ability to discriminate between active and 
inactive molecules. The database molecules were downloaded from the binding database337 
(http://www.bindingdb.org/bind/index.jsp) as well as sketched from literature (Table 5.2). 
Compounds having IC50 values up to 250 nM are considered active and above 1000 nM are 
considered inactive. We checked the molecular similarity of the active and inactive sets in terms 
of molecular scaffold, molecular weight, calculated logP to increase the confidence that the 
query is truly selective. The database was cleaned and duplicates were removed using canvas. 
We generated multiple conformers for each molecule using OMEGA with the following 
parameters: zero value for maximum number of conformers to ensure thorough conformational 
search without limiting the number of conformers, MMFF94s_NoEstat as search and 3D build 
force field, energy window of 10 kcal/mol, and the maximum number of rotatable bonds was set 
to -1 to allow for no maximum limit.  
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Table 5.2. Actives and decoys datasets. 
Dataset Number of compounds Number of conformers IC50 (nM) 
Actives 47 71393 0.2-250 
Decoys 18 92052 1000-10000 
 
 We performed model validation with vROCS335, 336 considering TanimotoCombo score 
for ranking, which is a combination between Tanimoto shape score (shape complementarity) and 
Tanimoto color score (common chemical features). 
 The following is the list of structures that we used in our validation step. The structures 
are diverse enough to account for all PERK inhibitors’ scaffolds213, 338-344 and to provide a good 
validation output. 
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2,3-dihydro-1H-indol-5-yl}- 1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
2,3-dihydro-1H-indol-5-yl}- furo[3,2-c]pyridin-4-amine 
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5.2.5. Collection of multiple kinases’ ligand databases 
We downloaded 1100 CDK1 inhibitors, 1100 CDK5 inhibitors, 300 GSK-3α inhibitors, 
and 1700 GSK-3β inhibitors as 3D SDF files from the binding database337. We divided the 
datasets into actives (all compounds that have IC50 ≤250 nM) and inactives (all compounds that 
have IC50 ≥1000 nM).  
We used LigPrep345 to prepare the databases using OPLS2005 forcefield and charges. We 
enumerated all possible protonation and ionization states for each ligand using Ionizer at a pH of 
7.4. The stereoisomers were generated if not assigned with a limit of 32 stereoisomers per ligand. 
We generated all possible tautomeric states. Finally, we kept only the lowest energy conformer 
for each ligand. 
 
5.2.6. Structure-based pharmacophore modeling 
To construct a structure-based pharmacophore we used MOE346. The PDB file was 
loaded into MOE and prepared (correcting any problems with the structure, adding hydrogens 
and assigning protonation states) using the structure preparation tool. Protonate3D was used to 
fix the rotamers of -SH -OH Cys, Ser, Tyr and Thr, the ionization states of the acidic and basic 
amino acid residues such as Arg, Asp, Glu, Lys, and His, and the tautomers of imidazoles (His) 
and carboxylic acids (Asp, Glu). Then the pharmacophoric regions were identified as colored 
annotation points based on ligand-receptor interactions. These annotation points were converted 
into pharmacophoric features. The features radius was adjusted according to the position of 
amino acid residues. Excluded volumes were determined based on the regions occupied by active 
site amino acids. 
 
 
214 
5.2.7. Receptor grid preparation 
We used OpenEye scientific software347, 348 (www.eyesopen.com) to create the receptor 
grids for CDK1, CDK5, GSK-3α and GSK-3β. The centroid of the docking box was defined 
either based on bound ligands (CDK5 and GSK-3β) or the amino acid residues identified in to be 
in the binding pocket (CDK1 and GSK-3α). The amino acids in the ligand binding pockets of 
CDK1 and GSK-3α are described in Chapter 2. The volume and dimensions of the grid box of 
each protein are defined for CDK1 as 8742 Å3 (18.33 Å x 19.33 Å x 24.67 Å), for CDK5 as 4991 
Å3 (16.00 Å x 17.33 Å x 18.00 Å), for GSK-3α as 8205 Å3 (18.33 Å x 25.33 Å x 17.67 Å), and 
for GSK-3β as 8292 Å3 (23.00 Å x 18.33 Å x 19.67 Å). The dimensions of the outer contour of 
the docking region was determined for CDK1, CDK5, GSK-3α and GSK-3β as 2096 Å3, 368 Å3, 
1686 Å3, and 667 Å3 respectively. In grid preparation we did not impose any kind of constraints. 
 
5.2.8. Ligand binding pocket detection for PKC-ε 
We used the geometry-based pocket detection algorithm283 (fpocket) to detect the valid 
ligand binding pocket of PKC-ε. We prepared the protein to determine the alpha sphere for 
distance-based clustering. All small polar clusters were discarded before defining the valid 
protein cavities. The pockets are ranked using the druggability score. Then we used OpenEye 
scientific software to create the receptor grid for docking347, 348. 
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5.2.9. Virtual screening for PERK modulators 
In order to identify new hits as PERK inhibitors, we performed a combined ligand and 
structure-based virtual screening, starting with 3D similarity search with ROCS335, 336 followed 
by pose fitting application349. 
 
5.2.9.1. Ligand-based virtual screening (ROCS similarity search)  
The prepared drug-like database of Zinc Natural Products was searched against the 
ROCS335, 336 query with and without considering a search cutoff. The search cutoff was 
determined from the validation step to be a TanimotoCombo score of 1.0 based on the scores 
distribution of the actives and decoys. This TanimotoCombo score was used to rank the resulting 
hits. The results of each run were used in the next step of pose fitting. 
 
5.2.9.2. Protein structure-based virtual screening (Pose fitting) 
To reduce the number of hits returned from pervious steps, we used POSIT349 to fit 
ligands within the active site occupied by the native ligand. 
 
5.2.9.2.1. Receptor generation 
Make pose receptor module of POSIT was used to automatically generate the receptor 
grid for pose fitting step. The allowed clashes between native ligand and protein amino acid 
residues were set in the range of acceptable mild clashes (≥ 0.2 Å < 0.65 Å interpenetration). 
Thus the resulting fits will have similar contacts with the amino acid residues as native ligand. 
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5.2.9.2.2. Pose fitting 
Ligand binding probabilities were calculated using POSIT. The hits resulted from the 3D 
similarity search were checked for receptor fitting by allowing mid clashes same as native 
ligand. The output poses were scored based on the similarity with native ligand and receptor 
binding. 
 
5.2.10. Virtual screening for multiple kinase modulators 
In order to pinpoint new leads as multiple kinases inhibitors (CDK1, CDK5, GSK-3α and 
GSK-3β), we prepared a multi-filter virtual screening workflow. We started with a docking 
benchmark analysis to set up the cutoffs for each kinase, followed by docking filtrations, 
clustering and hit selection. 
 
5.2.10.1. Docking benchmarking 
The compound databases are docking into their particular kinase using FRED of 
OpenEye scientific software347, 348. Standard docking precision was used specifying 1.0 Å in 
ligand translations and 1.5 Å in ligand rotations. One pose was saved for each compound. 
The actives and inactives were docked using the same protocol and the docking scores were 
compared to set up the cutoff for each kinase type. 
 
5.2.10.2. Multiple docking filtration 
The drug-like databases of small organic molecules and natural products were docked 
sequentially into each kinase. Each kinase was considered as a filter for the second step. We 
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started by docking the compounds into CDK1 using -8.5 kcal/mol as scoring cutoff. All survived 
compounds were then docked into CDK5 (cutoff of -8 kcal/mol), then into GSK-3α (cutoff of -9 
kcal/mol) and finally into GSK-3β (cutoff of -9 kcal/mol). The resulting compounds were then 
clustered. 
 
5.2.11. Clustering and selection of hits 
We selected a set of compounds to be processed for biological testing after clustering. 
The compounds were clustered using topological torsions method of CANVAS350-352. 
Topological torsions are illustrated as (NPI-TYPE-NBR) - (NPI-TYPE-NBR) - (NPI-TYPE-
NBR) - (NPI-TYPE-NBR), where NPI is the number of π electrons on each atom, TYPE is the 
atomic species and NBR is the number of non-hydrogen branches. 
NBR is calculated for the two end atoms as the total number of branches minus 1, and for 
the two central atoms as the total number of branches minus 2. After calculating the structural 
fingerprints based on topological torsions, we hierarchically clustered the compounds into 10 
groups using the similarity score, which is calculated by 𝑆 = 2𝐷&W/(𝑑& + 𝑑W) where di and dj are 
the number of distinct descriptors in structures i and j, and dij is the number of descriptors the 
two structures have in common. 
 
5.3. Results and discussion 
We used the Zinc databases of Natural products because of the well-addressed prominent 
role of plant-based systems in healthcare. Plant-derived traditional medicines are used by more 
than 65% of the world population according to the world health organization (WHO)329. Plant-
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derived compounds show a good example in drug discovery programs such as the development 
of antimalarial drugs, in particular quinine and artemisinin, the development of the 
bronchodilator chromolyn by modifying khellin from Ammi visnaga, the discovery of the 
antidiabetic drug metformin from galegine, which is a compound derived from Galega of 
ficinalis, and many other examples including verapamil, morphine and codeine from related 
compounds isolated from Papaver somniferum329. Most of the isolated compounds from natural 
sources violate the roles of drug-likeness, this why we need to curate the structural database first 
before going into computational expensive steps. Ligand preparation is a crucial step in computer 
aided drug design process. All ligands’ atoms were adjusted for charges and atom types during 
the filtration step. In order to start with a more drug-like database, several drug filters have been 
applied to eliminate all compounds that may have reactivity issues, unfavorable metabolic 
pathways, or poor bioavailability. Several criteria have been used to filter the large database into 
a drug-like one including; 1) Physical properties such as molecular weight, topological polar 
surface area (TPSA), and logP. 2) Bioavailability, such as atomic and functional group content, 
absolute and relative content of heteroatoms, and limits on a very wide variety of functional 
groups. 3) Molecular graph topology, such as number and size of ring systems, flexibility of the 
molecule, and size and shape of non-ring chains. We started with 22,724,825 synthetic small 
organic compounds and 166,210 natural product compounds. After filtration, we got 11,251,123 
and 28,614 for the synthetic and natural products, respectively. The number of conformers that 
were generated for each vendor natural product database is shown in Table 5.3. 
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Table 5.3. The number of conformers generated for each file. 
File ID # Compounds # Conformers 
ambintnp_p0.0.sdf  4901 74225645 
ambintnp_p1.0.sdf  7 196 
hitnp_p0.0.sdf 85 470730 
hitnp_p1.0.sdf 3 9 
ibsnp_p0.0.sdf 18571 187214251 
indofinenp_p0.0.sdf 24 172272 
indofinenp_p1.0.sdf 2 35884 
npactnp_p0.0.sdf 217 867349 
npactnp_p1.0.sdf 11 68596 
princetonnp_p0.0.sdf 1931 22619734 
princetonnp_p1.0.sdf 642 6925254 
sellecknp_p0.0.sdf 19 16017 
sellecknp_p1.0.sdf 3 4347 
specsnp_p0.0.sdf 109 274353 
specsnp_p1.0.sdf 14 6734 
tcmnp_p0.0.sdf 1858 10568304 
tcmnp_p1.0.sdf 111 299922 
uefsnp_p0.0.sdf  97 301088 
uefsnp_p1.0.sdf 9 7974 
 
 
To search for new PERK inhibitors, we used GSK2606414 (Figure 5.1) as a guide in our 
virtual screening protocol (Figure 5.2). We used the Zinc databases to prepare drug-like ones to 
use them through two different initial filters: 3D similarity and pharmacophore-based ones. Then 
the resulting compounds are pose fitted in PERK binding site using the structural information of 
the pocket and the bound ligand. The compounds are then clustered and 10 compounds are 
selected for biological testing.  
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Figure 5.1. Cartoon representation of PERK (PDB 4G31, right), helices are shown in red, beta 
sheets in yellow, loops in green and the ligand is shown in grey. GSK2606414 structure (left). 
 
 
 
Figure 5.2. Virtual screening workflow of PERK inhibitors. The ZINC databases pass through 
drug-like filters, then through shape and pharmacophore based filters, before being tested for 
fitting inside PERK receptors. Ten compounds were selected for biological screening after 
clustering. 
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The results of model validation showed an AUC (area under the curve) of 0.865 (mean 
value 95% confidence limits) (Table 5.3, and Figure 5.3) indicating that the query is predictive 
and will be able to separate actives from decoys. We changed the ranking score from 
TanimotoCombo to ShapeTanimoto, and the AUC has changed to 0.842 indicating that shape 
alone is a less selective tool to identify PERK actives from decoys and that colors 
(pharmacophoric elements) are an important addition to the query. We also used Tanimoto color 
to score compounds and the AUC has changed to 0.924 indicating the importance of common 
chemical features in discriminating between actives and decoys. The enrichment percentages at 
the following values: 0.5%, 1% and 2% were reported (Table 5.3). The formulation of 
enrichment that is used in ROCS is the ratio of true positive rates to the false positive rates of 
0.5%, 1% and 2%. Thus enrichment at 1% is the fraction of actives seen along with the top 1% 
of known decoys (multiplied by 100). We plotted the fraction of actives found on the Y-axis 
versus the fraction of decoys on the X-axis in ROCS curve to define the cutoff of 
TanimotoCombo score that we will use in the virtual screening. In ROCS curve the top scoring 
compounds are plotted closest to the origin. As well, we plotted the score Histogram as color-
coded histograms for the score distribution of the actives and decoys (Figure 5.4). Active 
compounds showed a distribution with higher frequency of obtaining a high score (i.e. further to 
the right of the plot). Based on that distribution, we set a cutoff for TanimotoCombo of 1.0 to be 
used in the virtual screening.   
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Table 5.4. Model statistical validation parameters. 
 Statistical Parameter  Significance  
AUC 0.865  
0.5% Enrichment  152.8  
1.0% Enrichment  74.5  
2.0% Enrichment  38.3  
 
 
Figure 5.3. The ROCS curve (top). The color-coded histograms (bottom).   
 
 
223 
As another filter we constructed a structure-based pharmacophore with MOE using the 
structural information from the PDB file of PERK in complex with GSK2606414. The 
pharmacophoric elements and excluded volumes were built and adjusted according to the 
surrounding amino acid residues (Figure 5.4). The constructed pharmacopphore was based on the 
protein-ligand interaction fingerprint of PERK- GSK2606414 complex and it has five elements; 
one hydrophobic centroid or aromatic center, two hydrophobic and two aromatic centroids 
(Figure 5.5). Also, it has multiple excluded volumes based on the occupied sites of the binding 
pocket. The pharmacophore contains one site for hydrogen bond donor and one site for acceptor 
(Figure 5.4). In the screening step we permitted partial matching of at least three features. 
 
 
Figure 5.4. Left, the pharmacophore model features: green for hydrophobic (Hyd), orange for 
aromatic (Aro), cyan for hydrogen bond acceptor (Acc) and purple for donor (Don). Right, the 
pharmacophore model with the excluded volumes as grey surface. 
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Figure 5.5. The pharmacophoric elements and the spatial distances between them. 
 
The resulting compounds from the shape- and pharmacophore-based screening of ZINC 
databases were passed into a more rigorous hit filtration step in POSIT of OpenEye. POSIT 
works by finding initial poses by exhaustive and discarding all clashing poses. The poses are 
then selected based on the information extracted from bound ligand, and then the poses are 
scored relative to native ligand. We kept all compounds that have more than 42% probability of 
similar binding to native ligand. The shape screening and pharmacophore searching of natural 
products resulted in 31 (Figure 5.6) and 340 compounds, respectively. For the ZINC database of 
synthetic compounds, we considered that all compounds should have ≥1.00 TanimotoCombo 
score in shape and ≤0.7 Å in pharmacophore-based screening. We kept the top 2000 ranking 
compounds after pose fitting. Canvas module of Schrödinger was used to calculate the binary 
structural fingerprints from the 2D structures for cluster analysis to select compounds for 
biological testing (Figures 5.6-5.10). 
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Figure 5.6. The resulting compounds from virtual screening after pose fitting shown as grey 
sticks. 
 
Figure 5.7. Selected examples of the compounds selected for biological testing compared to the 
native ligand (which is first to the left). 
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Figure 5.8. Examples of selected compounds showing how they fit well in the regions of 
negative and positive free energy. 
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Figure 5.9. Examples of selected compounds interacting with the calculated water molecules in 
the binding site. The upper two panels show seven waters and how they form hydrogen bonds 
with the surrounding amino acids and native ligand. The other panels show selected compounds 
and how they interact with these calculated waters. 
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Figure 5.10. Compounds selected for biological testing after pharmacophore screening. 
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To search for new multiple kinase’ inhibitors, we planned a multi-layer virtual screening 
workflow (Figure 5.11).  
 
Figure 5.11. Virtual screening workflow for multiple kinases’ inhibitors. 
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We filtered all ZINC databases using drug-like filtration rules. The constructed drug-like 
libraries were docked into CDK1 to generate a library of proposed CDK1 binders. The CDK1 
binders are then docked into CDK5, then to GSK-3α and GSK-3β to end with binders to all 
screened kinases. In the first step we retained ~11 Million compounds in the drug-like database. 
CDK1-based screening resulted in ~ 80,000, CDK5 in 40,000, GSK-α in 8000 and GSK-3β in 
500 compounds. Then we selected 10 compounds after clustering. The cutoff for each docking 
step was established during the benchmark analysis using active and inactive compound datasets. 
The number of compounds and activity ranges are described under the methodology section. 
Based on the benchmarking, we selected which model to use for CDK1 and GSK-3α, and a 
suitable PDB file for CDK5 and GSK-3β. The resulting compounds from these steps showed 
interesting interaction models. For example ZINC77470457 showed hydrogen bonding with the 
conserved Lys of CDK1 and Asp of the DFG region. Several calculated waters are observed ≤4 
Å around the ligand (Figures 5.11 and 5.12).  
 
 
Figure 5.11. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with 
CDK1. Waters are shown as spheres colored red (∆G>0) to green (∆G<0). 
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ZINC484412812 interacts with the hinge region and conserved Lys of CDK1 (Figures 
5.11 and 5.13). Some waters are displaced by the ligand (Figure 5.13). In CDK5, ZINC77470457 
forms hydrogen bonds with the hinge and with Asp of the DFG motif (Figure 5.14 and 5.15). 
ZINC484412812 forms one hydrogen bond with the conserved Lys and three with the hinge 
(Figure 5.14 and 5.16). Several waters are displaced by the ligands (Figures 5.17 and 5.18). In 
GSK-3α, ZINC77470457 forms hydrogen bonds with the conserved Lys and the hinge (Figures 
5.17 and 5.18) while ZINC484412812 forms salt bridge with Asp of the DFG region, hydrogen 
bonds with DFG-1 and the conserved Lys (Figures 5.17 and 5.19). The ligands displace several 
water molecules in the active site (Figures 5.18 and 5.19). For GSK-3β, ZINC77470457 shows 
hydrogen bonding interactions with the conserved Lys and GK+2 (Figures 5.20 and 5.21), while 
ZINC484412812 shows interactions with GK+3 and GK+4 (Figures 5.20 and 5.22). Several 
waters are observed around the ligand.  
 
Figure 5.12. 2D interaction model of ZINC77470457 with CDK1. Waters are shown as spheres 
colored red (∆G>0) to green (∆G<0). 
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Figure 5.13. 2D interaction model of ZINC484412812 with CDK1. Waters are shown as spheres 
colored red (∆G>0) to green (∆G<0). 
 
Figure 5.14. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with 
CDK5. Waters are shown as spheres colored red (∆G>0) to green (∆G<0). 
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Figure 5.15. 2D interaction model of ZINC77470457 with CDK5. Waters are shown as spheres 
colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are displaced 
by the ligand. 
 
Figure 5.16. 2D interaction model of ZINC484412812 with CDK5. Waters are shown as spheres 
colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are displaced 
by the ligand. 
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Figure 5.17. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with 
GSK-3α. Waters are shown as spheres colored red (∆G>0) to green (∆G<0). 
 
Figure 5.18. 2D interaction model of ZINC77470457 with GSK-3α. Waters are shown as 
spheres colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are 
displaced by the ligand. 
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Figure 5.19. 2D interaction model of ZINC484412812 with GSK-3α. Waters are shown as 
spheres colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are 
displaced by the ligand. 
 
Figure 5.20. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with 
GSK-3β. Waters are shown as spheres colored red (∆G>0) to green (∆G<0).  
 
 
236 
 
Figure 5.21. 2D interaction model of ZINC77470457 with GSK-3β. Waters are shown as 
spheres colored red (∆G>0) to green (∆G<0). 
 
Figure 5.22. 2D interaction model of ZINC484412812 with GSK-3β. Waters are shown as 
spheres colored red (∆G>0) to green (∆G<0). 
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   Figure 5.23. Compounds selected for testing against CDK1, CDK5 and GSK3α/β. 
 
We prepared a third virtual screening workflow for PKC-ε modulators (Figure 5.24). Our 
objective is to find new enzyme activators. It is reported that Bryostatin 1 (an PKC-ε activator) 
binds to C1B domain of the enzyme. The drug-like compounds of ZINC database were screened 
with structural similarity filter (≥50% to benzolactam fragment). The resulting compounds 
(~5000) were then docked into C1B domain. Then we clustered the compounds and selected 6 
compounds for testing. The possible ligand binding pockets of the C1B domain are defined using 
geometry-based cavity detection algorithm, fpocket283 (Figure 5.25). To validate the pockets, we 
docked Bryostatin 1 in both pockets (Figures 5.26-5.27). The pocket filled with cyan spheres 
(Figure 5.25) shows higher druggability score (0.59) than the one with purple spheres (0.47). 
Bryostatin 1 showed good fitting in both pockets with comparable ChemGauss4 score (-8.1 and -
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7.9). The selected compounds showed hydrogen bonding and hydrophobic interactions with the 
surrounding amino acids (Figure 5.28). 
 
Figure 5.24. Virtual screening workflow for PKC-ε modulators. 
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Figure 5.25. The 3D model of C1B of PKC-ε (left). Right: the detected ligand-binding pockets 
of C1B of PKC-ε. Pocket 1 is the one filled with cyan spheres. Pocket 2 is the one filled with 
purple spheres. 
 
Figure 5.26. The binding mode of Bryostatin 1 in pocket 1 
 
Figure 5.27. The binding mode of Bryostatin 1 in pocket 2 
 
 
240 
             
              
               
Figure 5.28. The 2D interaction models of potential PKC-ε activators. 
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5.4. Summary 
In order to identify new modulators for protein kinases targets in AD, we implemented 
three virtual screening protocols. The first protocol was a ligand and protein structure based 
approach in which we filtered a drug-like database of >22 millions compounds through two 
molecular filters: a 3D-shape query and a PERK-structure based pharmacophore model, relying 
on the published bioactive conformer of a PERK inhibitor which was co-crystallized with the 
PERK kinase domain. Then, the binding modes of the resulting compounds were predicted and 
scored using a pose-fitting approach. After clustering analysis, we obtained compounds with 
high probability of inhibiting the PERK kinase. In the second protocol, protein structure-based 
virtual screening was applied to find multiple-kinase inhibitors through a parallel docking 
simulations into validated receptor grids of CDK1, CDK5 and GSK-3 kinases. The highly 
scoring and unique compounds (based on the structural fingerprints) were selected for biological 
evaluation. In the third protocol, we searched for potential activators of PKC-ε by the 
implementation of a novel approach based on the structure of the C1B domain of PKC-ε and 
guided by the binding mode of bryostatin to the 3D model of C1B domain. 
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CHAPTER 6. FUTURE PLANS 
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We presented several computational explorations to study the targeting of six essential 
protein kinases in AD. The thermodynamic calculations of the active sites of these kinases 
provided beneficial strategies for the improvement of ligand affinity as well as ligand selectivity. 
Hence, we plan to use thermodynamic-directed lead modifications to enhance the activity of the 
identified hits from our VS workflows. 
 
Since we studied protein-protein interactions of CDK5-p25, one of the future plans is to 
define the binding pockets at the interface between CDK5 and p25. Then, we will apply the 
virtual screening protocol to target these protein-protein interactions using the defined pockets as 
filters. This strategy would be beneficial to design novel scaffolds as AD hits, and to achieve 
higher selectivity because CDK5-p25 complex is elevated significantly in AD brain.  
 
Because there is no known small molecule activator of PKC-ε, we plan to test the hit 
compounds which were identified from the virtual screening and to use a fragment-based 
strategy to build libraries of analogs that can be tested as PKC-ε activators. Fragment-based 
studied would emerge into synthetically feasible structures that can be synthesized or searched 
for their availability in structure databases.  
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